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1. Well established models of hemorrhage and sepsis in the rat have been 
used to study possible roles of prostaglandins (PGs) during these con¬ 
ditions. 
2. Direct measurement of plasma PGE and PGF0 levels before and during hemor- 
2a 
rhage, by radioimmunoassay, yields large variations and reveals no pat¬ 
terns of change. 
3. The single pass pulmonary metabolism of injected PGE£ was dramatically 
decreased following 75 minutes of hemorrhagic hypotension. Associated 
with the decrease in pulmonary PG metabolism was an increased retention 
of radioactivity by the lung tissue. This is the first in_ vvv£ demonstra¬ 
tion of altered metabolism of PGs during hemorrhage. 
4. Treatment with indomethacin, a well known inhibitor of PG synthesis, 
caused a significant decrease in survival following 75 minutes of hemor¬ 
rhagic hypotension at 40 mm Hg. These effects were not reversed by in¬ 
fusion of PGE^ (0.1 yg/kg/min) alone. 
5. In a model of sepsis produced by cecal ligation and puncture, indomethacin 
treatment during early sepsis was found to be deleterious. During late 
sepsis, however, indomethacin treatment did not further diminish the low 
survival rate of animals. The present results demonstrate, for the first 
time, adverse effects of indomethacin on survival following sepsis. This 




6. It is concluded that PGs have a protective role in hemorrhagic hypo¬ 
tension and early sepsis. The mechanism of protection is not known, 
but probably involves sparing of tissue ischemia by vasodilation. 
v i i i 

GENERAL INTRODUCTION 
Hemorrhage and sepsis are pathophysiologic situations characterized by 
significant alterations in circulatory dynamics, tissue perfusion, cellular 
energetics and function. These alterations lead eventually to cell death, 
organ failure, and, all too frequently, demise of the organism. Despite 
the vast literature dealing with clinical and experimental observations of 
shock, many questions remain unanswered (20, 42, 281). 
In particular, there are several major unanswered questions regarding 
the control of the vascular bed at several levels: the relationship of the 
pump function of the heart to the resistance and capacitance vessels; the 
relationship of organ function to organ perfusion during altered circulatory 
states; the interactions of the microvasculature with cell energetics and 
perfusion. 
Prostaglandins (PGs) have been demonstrated to produce striking effects 
on many tissues even at low concentrations. Two of the circumstances in 
which PGs have been implicated are hemorrhage and sepsis (184). Yet little 
is known concerning the effects and role of PGs during such adverse circu¬ 
latory conditions. Therefore, the studies described in this thesis were 
undertaken in an attempt to determine possible roles of prostaglandins in 





Hemorrhagic hypovolemia produces circulatory compromise in a number of 
different ways, as many reviewers have pointed out (20, 147, 281). The fun¬ 
damental problem during hemorrhage is decreased circulatory volume 
(239), which leads in turn to hypoperfusion, tissue hypoxia, and cell in¬ 
jury. The organism responds to this circulatory insult with a complex neuro- 
humoral response (6, 58, 71, 179, 223), which is designed to direct the resi¬ 
dual volume preferentially to vital organs (i.e., brain, heart, liver, and 
kidneys), even at the expense of other sites. This response is not entire¬ 
ly salutary in prolonged hypovolemia, however, since continued hemorrhagic 
hypotension is associated with several pathologic processes. The nature of 
these adverse processes has been recently reviewed by Zweifach and Fronek 
(281). 
Cardiac function, for example, has been found to deteriorate during 
prolonged hypovolemia (103, 153), despite the fact that coronary blood flow 
is preferentially maintained at adequate rates. Proposed explanations of 
the deterioration of cardiac function include: a failure of sympathetic 
output in late hemorrhagic shock; alterations in cell metabolism leading to 
decreased pump function; and the effect of toxic factors, such as "myo¬ 
cardial depressant factor" (92, 149). Another possibility is that the con¬ 
trol mechanisms in the coronary bed function less effectively during hypo¬ 
volemia; this might be due to alterations in any of a number of local and 
humoral factors, including the PGs. 

3. 
The circulatory failure resulting from hemorrhagic hypotension may pro¬ 
duce significant alterations in renal blood flow and function. In particu¬ 
lar the following effects are seen: the redistribution of blood flow in 
favor of the inner cortex and medulla (198), activation of the renin-angio¬ 
tensin system (178), and alterations in renal concentrating ability, which 
involve anti-diuretic hormone (ADH, ref. 234). The genesis of these changes 
is described as a complex interaction of neuro-humoral vasopressor effects 
and local vasodilation (17). 
Alterations in pulmonary blood flow and function during hemorrhage have 
been reviewed by Bryant et_ al_. (33 ) and, more recently, by Sykes (249). In 
brief, the pattern of intrapulmonary blood flow is changed so that the lower, 
dependent areas receive more flow (255). These gravity favored areas have 
been identified as the site of subsequent changes in capillary permeability 
(49, 131, 233, 254) and of malfunction of surfactant-producing Type II pneumo- 
cytes (176). These changes may also contribute to decreased compliance (50) 
and to the increase in pulmonary vascular resistance (83). In addition, al¬ 
terations in the pulmonary vascular bed and capillary endothelial membranes 
may lead to changes in other non-respiratory functions of the lungs, such as 
metabolism of circulating hormones (89). 
Immunologic (8) and hematologic (158) changes have also been documented 
during hemorrhagic hypotension. It must be borne in mind, however, that ex¬ 
perimental techniques, including heparinization, may contribute to these 
changes. Alterations in hepatic function have also been well documented 
during hemorrhage, and recent work has correlated functional changes with 
alterations in cell ultrastructure and function (87). 

4. 
A recurrent theme in the above mentioned alterations in organ function 
is the associated changes in regional blood flow. These effects appear to 
be mediated by catecholamines and humoral vasoactive substances, but modu¬ 
lated subsequently at the level of the microvasculature (281). 
The microvasculature is itself subject to diverse factors during hemor¬ 
rhage, including acidosis (140, 274), catecholamines (6), and the kallikrein 
kinin system(25, 220). There may be other factors which affect the micro¬ 
vasculature, such as prostaglandins (167) and unidentified local metabolites 
The response of the microvascular bed has been observed during hemorrhage by 
direct microscopy. In skeletal muscle (107, 121) hemorrhage induces con¬ 
striction of small arteries and veins in the early stages, followed by ve¬ 
nous dilation at a later stage. In the enteric bed (85) no changes in ar¬ 
terial or venous tone have been noted, but capillary flow has been observed 
to decrease. These changes are consistent both with the decrease in blood 
flow to most vascular beds and with the degree of variation from tissue to 
tissue of vasoconstriction-vasodilation. 
) 
The consequences of diminished flow during hemorrhage have also been 
documented at the cellular level. The effects which have been observed in¬ 
clude the production of hypoxia (196, 240), alterations in cell membrane 
function leading to changes intracel1ular fluid and electrolytes (64), and 
significant alterations in cellular energetics (21, 38). The defect in cell 
energy production may be due to many factors, among which the following are 
prominent: altered microcirculation which may limit substrate availability 
to cells; membrane alterations which include defects in membrane transport 
(224) and response to hormones (40); and changes in the capacity of cells to 
provide energy for or to control active transport. Decreases in cellular 
. 
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cyclic nucleotide levels and high energy phosphate compounds have been docu¬ 
mented during hemorrhage (39). Since many intracellular functions are ener¬ 
gy requiring, the documented decrease in available intracellular energy stores 
may impair tissue function as well. Indeed, this has been documented (21). 
In summary, hemorrhagic hypotension might be conceived as the stimulus 
for the organism to respond with measures which simultaneously vasoconstrict 
and vasodilate. The former is protective of critical organs and is due to 
the action of sympathetics, renin-angiotensin, and perhaps other humoral 
substances. Vasoconstriction when prolonged is, however, injurious to cells. 
The organism must also respond with actions to mitigate the injurious ef¬ 
fects of vasoconstriction. It does so by vasodilation of local micro- 
vascular and small vessel beds. A key to understanding the pathophysiology 
would appear to lie in the interaction of neuro-humoral and local factors at 
the level of the local circulatory bed. 
2. Sepsis 
For the sake of clarity, sepsis is defined here as the severely altered 
pathophysiologic state resulting from infection, with or without associated 
septicemia. In spite of the frequent occurrance of sepsis, little is known 
of the complex mechanism by which such serious infections alter physiologic 
parameters and lead to high mortality (170, 271). A number of investigators 
have attempted to address the problem of the pathophysiology of sepsis and sev¬ 
eral approaches have been used. Previous work falls into three broad classes: 
clinical studies of septic patients; animal models using purified endotoxin; 
and animal models of bacteremia, usually produced either by injection of live 
organism, by abscess formation, or by peritonitis. The relationship of the 
experimental models to clinical observations is still unclear (271). 

6. 
The many clinical descriptions and studies (37, 55, 108, 146, 170, 177, 
189, 267, 275, 276) have been concerned, in general, with empiric observation 
of the clinical syndrome, although the more recent advent of clinical hemo¬ 
dynamic monitoring has afforded the possibility of documenting the dramatic 
hemodynamic and metabolic alterations which occur during sepsis. Briefly, 
the clinical studies document an early "warm" phase, characterized by in¬ 
creased cardiac output, vasodilation, hyperventilation, and hyperglycemia. 
This is followed by the "cold" phase, which is associated with diminished 
cardiac output, vasoconstriction, hypovolemia, oliguria, acidosis, hypo¬ 
glycemia, and high mortality (42, 146, 267). Sepsis, therefore, is a com¬ 
plex and evolving phenomenon, which is capable of producing profound physio¬ 
logic alterations. 
Christy has written a thorough review of the pathophysiology of sepsis, 
although it is vintage 1971 (42). He describes several features associated 
with sepsis. These include: 1.) depression in cardiac, renal, and pul¬ 
monary function in the late stage of sepsis; 2.) marked increases in many 
humoral factors, such as acetylcholine, bradykinin, catecholamines, hista¬ 
mine, and serotonin; 3.) decreases in other circulating factors such as 
coagulation factors and complement; 4.) coagulopathy; 5.) a major immuno¬ 
logic-inflammatory reaction; and 6.) significant changes in the micro- 
circulation. The microcirculatory changes are characterized pathologically 
(169) as a generalized Shwartzman reaction. The underlying mechanisms for 
the phenomenologically observed alterations, however, are not known. 
The prominence of immunologic features in sepsis has prompted investiga¬ 
tion and mechanistic speculation concerning the role of endotoxin in sepsis. 

7. 
Endotoxin is a 1ipopolysaccharide present in the cell wall of most gram¬ 
negative organisms (60), which, when injected into animals, produces hemo¬ 
dynamic alterations similar to those described in late sepsis (260), as well 
as high mortality. Because of these observations, many investigators have 
studied endotoxin shock as a model of sepsis, assuming that their observa¬ 
tions of endotoxin effects will contribute to the understanding of human 
sepsis and help to formulate treatment programs for clinical use. This is 
not necessarily true(271). Some features of sepsis, such as activation of 
immunologic host defense systems, may be ascribed appropriately to endotoxin 
(175), but other features, such as hemodynamic effects, cannot be so read¬ 
ily assumed to be due to endotoxin. Furthermore, study of endotoxin shock 
has been plagued by other problems, such as: 1.) variations in endotoxin 
preparations which may lead to vastly different effects (175); 2.) confu¬ 
sion over amount of endotoxin to be administered, for it is likely that 
large doses (LD^qq, with 2-20 mg/kg) correspond more nearly with anaphy¬ 
laxis than with bacteremia; and 3.) species variations which further com¬ 
plicate efforts to translate conclusions based on endotoxin studies to hu¬ 
man sepsis. Finally, there is confusion over the actual role of endotoxin 
in clinical sepsis, since quantification has detected concentrations of 
endotoxin in the range of pi cograms per milliliter; this differs from ex- 
r 
perimentally used quantities by a factor of 10 (209, 271 ). 
Animal models of bacteremia, as recently reviewed by Wichterman and 
associates (271), have been intended to reproduce more accurately human sep¬ 
sis. The major difficulty with these models has been reliability and repro¬ 
ducibility of the bacteremic insult. A recently described model of cecal 
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ligation and puncture in the rat has been found to cause bacteremia in all 
animals within six hours and to produce a high mortality rate (272). In 
addition, this model is notable for its imitation of the hemodynamic and 
metabolic alterations of human sepsis, in particular for an early phase of 
hyperdynamic circulation and hyperglycemia (272) and a later phase of de¬ 
pressed hemodynamics and hypoglycemia. Similar hemodynamic findings have 
been documented in a canine model (143). It is hoped that these models 
will allow inquiry into the mechanism of septic injury, without the com¬ 
plicating concerns of applicabi 1 ity, as has been noted for endotoxin models. 
In summary, the clinical features of sepsis have been observed and re¬ 
ported by many authors, but the roles and significance of the various fac¬ 
tors are still largely unknown. Concern over the appropriateness of various 
animal models has made the pathophysiology of sepsis difficult to understand 
in a controlled manner. 
3. Prostaglandins 
Prostaglandins (PGs) are a set of ubiquitous compounds which have been 
the subject of extensive research during the past decade and the subject of 
an equally extensive literature. Because this literature is so immense, it 
will not be possible to delineate all of the PG effects in this section. 
The major effects of PGs are, however, listed below, and a more detailed 
description is provided in the Appendix (p.73). 
The PGs are unsaturated fatty acid derived compounds synthesized by 
virtually every type of mammalian tissue yet studied. The biosynthesis re¬ 
quires the release of arachadonic acid (AA) from cell membrane phospholipids, 
which occurs following a number of physical, chemical, and physiological 
' 
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alterations. AA is then transformed by a series of membrane bound enzymes, 
as shown in Figure 1, into the PGs: PGE, PGF, PGI, and thromboxane A (TXA). 
These are the compounds of greatest physiologic significance. The plasma 
half-lives of these PGs are short, however, ranging from 30 seconds (TXA^) 
to a few minutes (PGs E, F, and l^). The primary PGs (PGE and PGF) are in¬ 
activated in the pulmonary vascular bed, primarily by the action of the 
intracellular enzyme 15-hydroxy-PG dehydrogenase. PGI and TXA are broken 
down primarily by hydrolysis in plasma. The pulmonary metabolism of the 
primary PGs assures, in general, that the effects of these two PGs (E and F) 
are primarily local tissue effects. 
The variety and magnitude of effects which PGs evoke are striking. 
For the most part, the vascular effects of PGs may be summarized by the 
statement that PGE0 and PGI0 are vasodilators and PGF0 and TXA0 are vaso- 
c c ca c 
constrictors. This has been noted in many vascular beds in a number of 
species, although there are exceptions. For example, the rat renal bed has 
been found to vasoconstrict in response to PGE2. 
The PGs have a number of renal effects as well. They are thought to 
constitute a major part of the renal vascular autoregulatory response. In 
addition, they are thought to contribute to the control of systemic blood 
pressure, to the control of renin release, to adjustment of fluid and 
electrolyte balance, and to mediation of erythropoietin synthesis stimulation. 
In the lungs PGs have bronchial smooth muscle effects analogous to 
those in vascular smooth muscle. Thus, PGE^ is bronchodilatory and PGF^ 
is bronchoconstrictive (PG^ and TXA^ are largely unstudied, since they 
are relative newcomers to the field). The PGs are thought also to contri¬ 
bute to the pulmonary response to hypoxia and anaphylaxis. 
. 
. 
FIGURE 1 10. 
BIOCHEMISTRY OF THE PROSTAGLANDINS (PGs) 
Membrane 
Phospholipids 





1 : Phospholipase A^ 
2- Cyclooxygenase 
3: PG Endoperoxide E Isomerase 
4: PG Endoperoxide Reductase 
5: Prostacyclin Synthetase 
6: Thromboxane Synthetase 
7: 9-keto Reductase 
8: 15-hydroxy-PG Dehydrogenase 
9'. PG A13 Reductase 
10: non-enzymatic hydrolysis 
11: non-enzymatic hydrolysis 
1: Corticosteroids (?) 
2: Nonsteroid anti-inflammatory 
agents (aspirin, indomethacin, 
etc.) 
5: 1 5-peroxy-arachadonic acid 
6: Imidazole, benzydamine 
8: Indomethacin, ?furosemide 
-• 
The gastrointestinal effects of PGs include smooth muscle activity 
(PGE^ modulates motility) and protective effects against ulceration. The 
endocrine effects are prominent in the reproductive system. Recent investi¬ 
gations have implicated PGs and cAMP in the control of hormone release. 
In the nervous system both central and autonomic effects have been de¬ 
scribed. Mediation of fever and neurotransmission effects have been ascribed 
to PGs in the central nervous system. More important are the autonomic ef¬ 
fects: PGE,-, inhibits adrenergic release prejunctionally and enhances choli¬ 
nergic release; PGE2 also, in general, modulates effects of sympathetic stimu¬ 
lation of vascular tissue by vasodilation. 
Control of local circulation seems to be a major function of the PGs. 
Not only do vasodilatory PGs oppose the vasopressor effects of adrenergic 
stimulation, but they also appear to modulate or mediate the effects of a 
number of circulating vasoactive factors as well, such as angiotensin and 
bradykinin. In general, the PGs seem to function as homeostatic regulators 
of local circulatory beds in response to stimuli noxious to tissues. 
Recent work indicates that PGI^ and TXA^ play major and opposing roles 
in the control of platelet aggregation. PGI2 inhibits aggregation, whereas 
TXA2 is a potent stimulus for platelet aggregation. 
The central mechanism of PG action, as has been learned principally 
from the study of platelets, is modulation of intracel 1 ular cAMP. The PGs 
have also been implicated in the control of intracellular calcium movements 
and stores. The precise details, however, of the interactions of the PGs, 
2+ 
cAMP, and intracel1ul ar Ca are still unknown. 
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It may be taken as a general hypothesis that the PGs subserve the func¬ 
tion of membrane messengers, i.e., the release of PGs from altered or in¬ 
jured membranes leads to stimulation of cells. Whether the cell(s) which 
is influenced is the same cell, nearby, or distant is still a matter of in¬ 
vestigation, although most investigation suggests that PGs are primarily 
local hormones, affecting nearby cells. 
Study of PGs and PG effects have benefited greatly from the use of in¬ 
hibitors of PG synthesis, particularly the nonsteroidal anti-inflammatory 
drugs, such as aspirin and indomethacin (see Figure 1, step 2). The di¬ 
rect measurement of PGs, on the other hand, has been problematic and the 
significance of plasma PG levels has also recently been questioned. More¬ 
over, the PGs are present in tissues in small concentration and are effect¬ 
ive in equally small concentrations (i.e., 10~^ to 10~^ M). Thus, ordinary 
biochemical measurement techniques are not useful. Instead, very sensitive 
assays must be used. At present, radioimmunoassay and gas chromatography- 
mass spectrometry are the best methods of measurement; the latter is cur¬ 
rently believed to be the more dependable. 
; 
13. 
REVIEW OF RELEVANT LITERATURE 
There are a number of clinical and experimental studies which indicate 
that alterations in PG synthesis may be involved in the pathogenesis or 
manifestations of a number of clinical situations. Associated with increased 
PG synthesis and concentrations are: trauma, burns, shock, sepsis, malignant 
tumors, fever, subarachnoid hemorrhage, pulmonary hypertension, and perhaps 
others (184). On the other hand, patent ductus arteriosus, peptic ulcer, 
renal ischemia, and others have been associated with decreased PG synthesis 
(184). These, in conjunction with the striking effects observed at low PG 
concentrations, suggest that they may play a role in the altered circulatory 
dynamics of hemorrhage and sepsis. Several previous investigators have ex¬ 
amined some aspects of this question. 
1. Hemorrhage and Prostaglandins 
The circulatory insult of hemorrhagic hypotension is precisely the cir¬ 
cumstance in which one might expect to find increased PG synthesis. This is 
due to the fact that the microcirculation is affected during hemorrhage and 
cells are subjected to hypoxia, which is a potent stimulus of PG synthesis 
(161). The decreased blood flow to organs and tissues, which leads to al¬ 
tered cell functions throughout the organism, might lead specifically to a 
depression of cell membrane transport and metabolism of PGs by the endotheli¬ 
um in the lung. This, in turn, might subject the organism to further in¬ 
creased PG levels. In attempting to understand the role of PGs during 
hemorrhage, a number of investigators have used several different approaches. 
These have included: 1.) direct measurement of plasma PG levels during 
. 
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hemorrhage; 2.) assessment of metabolic capabilities of organs and cells to 
inactivate PGs; and 3.) use of pharmacologic inhibition of PG synthesis or 
of exogenous PGs to alter survival or physiologic parameters. 
The possibility of direct measurement of plasma PG levels has attracted 
several investigators. Most have measured PGE levels, since PGE has signifi¬ 
cant vasodilatory actions, which might either ameliorate local blood flow or 
exacerbate systemic hypotension. PGE also has effects related to a number 
of other vasoactive stimuli, i.e., sympathetic stimulation, angiotensin, and 
bradykinin, so that alterations in PGE levels may affect the vasomotor activi¬ 
ty of these entities. PGF2a has been studied rarely, perhaps because its 
vascular activity is not believed to be as significant physiologically. 
Studies concerning the newer PG compounds, PG I ^ and have not yet been 
reported. 
The first report of elevated PGE during hemorrhage was that of Flynn 
and associates (80). They subjected the anesthetized dogs to hemorrhagic 
hypotension to 60 mm Hg and obtained arterial blood for determination of 
plasma PG levels by RIA. They found an increase in plasma PGE from 0.34 to 
1.3 ng/ml after 90 minutes of hypotension. They also reported increased 
levels, from 0.62 ng/ml baseline to 1.25 ng/ml after 60 minutes. Jakschik 
and co-workers (129) subjected anesthetized dogs to 45-50 mm Hg hemorrhagic 
hypotension and used bioassay to determine arterial PGE levels. These investi¬ 
gators found an increase from control levels which were immeasurably low to 
levels of 2.6 ng/ml after 30 minutes; they associated the above time with 
maximal compensation. Johnston and Selkurt (132) subjected animals to hemor¬ 
rhage to achieve 60 mm Hg hypotension for 90 minutes, followed by further 
bleeding to 35-40 mm Hg. They observed an increase in PGE levels, as 
ft!’ 
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measured by RIA, from 450 pg/ml to 740 pg/ml in arterial samples. These in¬ 
vestigators (132) also measured renal output of PGE by renal vein sampling 
and found that PGE output did not change during the period of hemorrhage. 
When shed blood was reinfused, however, they noted a striking increase in 
renal output of PGE from 8 ng/min baseline and during hemorrhage to 109 ng/min. 
Most recently, Frolich (89) has reported increased PGE^ levels in aortic blood, 
but not in right atrial blood, during an undescribed hemorrhagic insult in 
both anesthetized and unanesthetized dogs. Using gas chromatography-mass 
spectrometry (GC-MS) he found a tremendous increase in PGE^ from basal values 
of less than 50 pg/ml to values greater than 10000 pg/ml after 30 minutes 
of hemorrhage. Thus, it appears on the basis of these studies (80, 84, 129, 
132) that PGE2 levels increase during hemorrhage in dogs. 
The possibility has been raised that part of the elevated arterial PGE^ 
levels might be the result of diminished pulmonary metabolism of circulating 
PGE. Hissen et a]_. (117) presented data in 1969 that in retrospect suggests 
decreased metabolism. They found that PGE-| injected intravenously during 
hemorrhage produced increased arterial levels as assessed by increased inhibi¬ 
tion of platelet aggregation. Jakschik and associates (128) lent support to 
the hypothesis of decreased pulmonary metabolism. Using bioassay, they found 
an increase in the ratio of arterial to venous PGE. Blasingham and Selkurt (30) 
and Fletcher and Ramwell (74) reported similar findings using RIA. They docu¬ 
mented a decrease in extraction ratio of PGs using mixed venous and arterial 
blood. (1 -(A/V)). The findings of these three groups (30, 74, 128) are con¬ 
sistent with those of Frolich (84) using GC-MS. These four investigations, 
however, could not distinguish decreased metabolism from increased pulmonary 
synthesis and release of PGE during hemorrhage. Indeed, Frolich's data support 
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the latter as the more important factor. On the other hand, Flynn and Lefer 
(81) found no decrease in the ability of rabbit liver, kidney, or lung homo¬ 
genates to metabolize PGE or P6F following systemic hypotension. Whether or 
not the altered metabolism seen in vivo by previous workers (30, 74, 117, 128) 
was reversed by isolation and handling is not clear, however, so that caution 
must be used in accepting the data of Flynn and Lefer (81) as evidence of in¬ 
tact metabolic capacity. Nevertheless, the different in vivo and in vitro 
findings do create confusion concerning the issue of alterations in pulmonary 
metabolism of PGs during hemorrhage. 
The experimental use of PG synthesis blockade both as therapeutic inter¬ 
vention and as pharmacologic tool has attracted many investigators. Jakschik 
and co-workers (129) noted an increase in mean arterial pressure (MAP) and 
an increased blood loss following a moderate dose of indomethacin (1-2 mg/kg). 
Johnston and Selkurt (132) reported that the same dosage of indomethacin did 
not affect the small increase in arterial PGE they had observed, but did 
block the large increase in renal release of PGE during reinfusion. The 
thorough study of Leffler and Passmore (150) showed that indomethacin in¬ 
creased systemic blood pressure by increasing systemic vascular resistance 
in dogs subjected to 3.5 hours of severe hypotension. These authors hemor¬ 
rhaged animals to 30 mm Fig and gave indomethacin once the MAP began to fall 
after reinfusion. In particular, their investigation demonstrated increased 
vascular resistance in the heart, brain, gut, and kidney, as well as a 57% 
diminution in renal blood flow. This study (150), therefore, suggests a pro¬ 
tective role for PGs in late hemorrhagic shock. 
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A number of other reports have documented (by PG synthesis blockade) 
the importance of PGs in the renal bed during hemorrhagic hypotension. Bell 
et. al_. (23) showed that indomethacin inhibits the recovery of renal blood 
flow following hemorrhage to 30 mm Hg. Using microspheres, Data and co¬ 
workers (47) demonstrated decreased renal blood flow in animals treated with 
8 mg/kg indomethacin prior to a 33% reduction in MAP. They noted that the 
decrease in blood flow was particularly evident in juxtamedul1 ary nephrons 
and in the cortex. Tyssebotn and Kirkeb0 (259) found similar results using 
platinum electrode measurement of renal blood flow in dogs bled to 50 mm Hg. 
They suggested that PGs play a role in dilating vessels throughout the kid¬ 
ney. The studies of Henrich and associates (110, 111) have shown that PG 
blockade with indomethacin or with R020-5720, a peripheral blocker of PG 
action, leads to diminished blood flow and glomerular filtration rate. They 
also showed that the combined effects of denervation and angiotensin II block¬ 
ade returned blood flow to rates found in animals not treated with PG block¬ 
ade. These studies strongly suggest that PG synthesis is increased in the 
renal bed, perhaps to counteract the effects of the renal sympathetics and 
of circulating angiotensin II, thereby maintaining renal blood flow. Thus, 
it appears that renal PGs exert a protective vasodilatory effect during 
hemorrhagic hypotension. This notion is consistent with studies on acute 
renal failure induced by renal artery clamping (127) and by glycerol admini¬ 
stration (258, 270). 
The work of Gerkes and Shand (87) on hepatic artery autoregulation is 
analogous to the studies on the renal bed described above. These investiga¬ 
tors found that indomethacin increased hepatic artery resistance during 33% 
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hypotension as compared with untreated animals. This observation suggests 
that PGs play a role in vasodilation in the hepatic bed. 
Studies have also been conducted to determine whether exogenous PG 
would ameliorate the effects of hemorrhagic hypotension. Glenn (91) re¬ 
ported that intravenous infusion of PGF^ led to prolonged survival time in 
cats subjected to a lethal hemorrhage protocol. Priano et al. (211) reported 
increased survival time and improved cardiopulmonary function in anesthetized 
dogs bled to 40 mm Hg and given an intraventricular infusion of PGE-j at a 
rate of 0.4 yg/kg/min. Machiedo and associates (154, 155) reported prolonged 
survival and improved cardiac and respiratory function in anesthetized dogs 
bled to 30 mm Hg and maintained until they received 25% of shed blood, at 
which time the remaining shed blood was returned and intravenous PGE-j was in¬ 
fused at a rate of 1 yg/kg/min. Finally, in a more recent paper, Flynn and 
Lefer (82) found that infusion of arachadonic acid intravenously (120yg/kg/min) 
had a beneficial effect on lysosomal enzymes, but not on hemodynamic function. 
A slightly beneficial effect on survival was observed (82). 
Thus, it appears from the studies of infusion of PGs E and F and of the 
precursor AA during hemorrhage that each of these may have a salutory effect. 
All infusions were capable of improving survival in lethal hemorrhage models. 
On the other hand, the small number of animals used in these studies of PG 
infusions raises serious doubt concerning the validity of the conclusions 
drawn from these experiments. Moreover, it should be noted that infusions 
were given intravenously in most of these studies. Since PGs E and F are 
rapidly inactivated by the pulmonary vascular bed in normal circumstances, 
there is cause for concern that infused PG would be largely metabolized 

19. 
in one passage through the lung. On the other hand, as was noted above, the 
metabolism of primary PGs is apparently diminished during hemorrhage. The 
amount of PG reaching the tissues in these studies (91, 154, 155) remains, 
therefore, unknown. The salutory effects of intraventricular PGE-j (211) 
are comparatively minor and based on small numbers of animals. AA, however, 
is not affected adversely by passage through the pulmonary vascular bed (122) 
and infusion of this compound during hemorrhage has been shown to be bene¬ 
ficial (82). This study cannot, however, distinguish which PG, whether a 
primary PG (PGE or PGF) or a different PG, such as PGor TXA^, is bene¬ 
ficial during hemorrhage. The above study is also supported by the finding 
that total inhibition of PG synthesis by indomethacin is detrimental to or¬ 
gan function, such as kidney function (110, 111). 
The studies described above indicate that arterial PGE^ levels are 
elevated during hemorrhage and that associated with this increase was an 
equivocal decrease in the ability of the pulmonary bed to inactivate circu¬ 
lating PGE. The effect of PG synthesis blockade appears to be deleterious to 
renal autoregulation, but no convincing effect on survival following hemor¬ 
rhage has been documented. Finally, PG infusion during hemorrhage appears 
to be beneficial, although little data is available regarding this aspect. 
2. Sepsis, Endotoxin Shock, and Prostaglandins 
A large number of studies have been conducted to determine possible 
roles for PGs in sepsis and sepsis-like states. Of these many studies, 
only one has used an animal model of bacteremia. The remainder have all 
used endotoxin, generally derived from Escherichia coli, although not necessa¬ 
rily from the same bacterial strain. The endotoxin has, however, generally 
been obtained from a common commmercial source. 
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The single study of PGs in bacteremia was reported by Culp and co- 
g 
workers (46). These investigators injected an LD-jqq dose of col i, 4x10 
organisms/kg of the enteropathic Dunwald strain, into anesthetized dogs and 
observed a slow decrease in MAP to 45% of baseline values 1 hour after in¬ 
jection. This effect persisted for the remaining three hours during which 
the animals were observed and was associated with an increase in portal vein 
pressure. Pretreatment with indomethacin (20 mg/kg) or with other anti¬ 
inflammatory drugs (flufenamate, aminopyrine, and phenylbutazone) was found 
to reduce the decrease in MAP and to improve survival. The increased sur¬ 
vival reported, however, was not statistically significant in this study. 
Prostaglandin levels during endotoxin shock have been the subject of a 
number of reported studies. Anderson et. a]_. (12, 14), using RIA, measured 
plasma levels of PGE and PGF 60 to 90 minutes after administration of endo¬ 
toxin. They found PGE levels to increase from baseline 0.27 ng/ml to 6.1 
ng/ml after 60 minutes and PGF concentrations to increase from 1 to 5 ng/ml 
during endotoxemia. Collier and co-workers (43) also found increased PGE£ 
levels in renal vein plasma during endotoxemia, as measured by bioassay 
(to 2-8 ng/ml). Kessler et al_. (138) also found a vasodilating substance 
in plasma following injection of endotoxin, which they inferred to be a PG. 
Herman and Vane (113), using bioassay, reported increased renal vein PGE2 
and PGF^ following endotoxin administration, but found no increases in ar¬ 
terial, inferior vena cava, or femoral vein samples. Isakson and associates 
(124) obtained similar results. Most recently, Fletcher and Ramwell demon¬ 
strated increased PGF^ (by RIA) in arterial and venous plasma of dogs (73) 
and baboons (76) durinq endotoxemia. They obtained PGF0 levels in the 
2 a 

rangeof 100 pg/ml which increased to 400 pg/ml following E. coli endotoxin in¬ 
jection. Administration of endotoxin to calves has been demonstrated to pro¬ 
duce increased pulmonary synthesis of PGF^, associated with pulmonary hyper¬ 
tension (13, 15). This finding is strikingly similar to anaphylaxis in the 
calf (5). Thus, a number of investigations have documented increase in PGE 
levels (12, 14, 43, 113, 124) or in PGF2 levels (12-15, 73, 76, 113, 124) 
following endotoxin administration. There is, however, disagreement about 
both the site of synthesis and the absolute levels of PGE. Moreover, these 
results have not been substantiated using GC-MS. 
There has been only one study reported concerning in vivo metabolism 
of PGs during endotoxemia. Fletcher and Ramwell (74) demonstrated increas¬ 
ed PG extraction ratios in baboon subjected to LD-jqq endotoxin. Two groups 
of investigators have described in vitro data. Nakano and Prancan (187) 
noted a marked diminution of PG metabolism by cell free systems derived from 
rat liver and kidney following an LD^q dose of endotoxin. Subsequently, 
they have reported (210) a decreased activity of PGDH in rat lung homogenates 
following administration of a large dose of endotoxin (10 mg/kg). These 
findings, however , are contrary to those reported by Flynn and Lefer (81). 
These investigators found no decrease in PG metabolic capabilities of rab¬ 
bit lung, liver, and kidney homogenates following endotoxin administration. 
Thus, the question whether pulmonary metabolism of PGs during endotoxemia is 
altered remains unanswered. 
The question of the role of PGs during endotoxemia has interested a 
number of investigators. The approach used by many has been the use of 
pharmacologic blockade of PG synthesis using indomethacin or aspirin. 

22. 
Erdos and colleagues (63, 116) found that both indomethacin and aspirin 
blocked both the acute (2 minutes after injection) systemic hypotension and 
pulmonary hypertension and also the delayed hemodynamic and metabolic altera 
tions of endotoxemia in dogs. The hemodynamic parameters which were observ¬ 
ed were systemic pressure, cardiac output, and portal vein pressure; the 
metabolic parameter was arterial pH. These early studies in dogs have been 
subsequently confirmed by Hall et al_. (104), Herman and Vane (113), Hilton 
and Wells (115), and the group of Fletcher et al. (72, 73). In addition, 
the latter two groups reported increased survival, as assessed by survival 
time (115) and by increase in number of survivors from 46% to 100% following 
treatment with indomethacin or aspirin (72). 
The existence of marked species variations in response to aspirin has 
been documented. Hall et_ aj_. (104) showed that both cats and sheep had more 
striking acute hemodynamic alterations, which were aspirin sensitive. These 
investigators also found, however, that the delayed effects of hypotension 
and acidosis were both of smaller magnitude and less responsive to aspirin 
in cats and sheep than in dogs. Greenway and Murphy (66) also described 
marked acute physiologic alterations in cats given Salmonella enteriditis 
endotoxin, which they found to be eradicated by aspirin pretreatment. 
Parratt and Sturgess demonstrated amelioration of acute changes in endo- 
toxemic cats using indomethacin, meclofenamate, and flubiprofen (203-206). 
They also reported improved cardiovascular function and diminished acidosis 
following treatment with these three structurally different PG synthesis in¬ 
hibitors, but did not obtain statistically significant increases in survival 
Reichgott and Engelman (214) found that indomethacin did not alter survival 
■ 
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in rats subjected to endotoxin shock. Studies in baboons have revealed that 
indomethacin or aspirin improved acute hemodynamics in animals given a mas¬ 
sive dose of endotoxin (LD-jqq, 20 mg/kg, ref. 76). Baboons subjected to a 
less severe endotoxemia (LD^q) showed no benefit of indomethacin on delayed 
hemodynamic parameters, but did show an increase in survival rate following 
indomethacin treatment (75). 
The effects of PG synthesis blockade on organ function in endotoxin 
shock has been studied only by Isakson and co-workers (124). They found im¬ 
provement in systemic blood pressure and decreased renin output following in¬ 
domethacin pretreatment of canine endotoxemia. These authors did not, how¬ 
ever, comment whether renal function or blood flow was altered. 
From these studies of PG synthesis blockade in endotoxin shock, three 
conclusions may be drawn: 1.) administration of large doses of endotoxin 
causes a species specific anaphylactic reaction, the hemodynamic element of 
which is partly dependent on PG synthesis; 2.) the delayed effects of endo¬ 
toxin, i.e., hypotension, may be improved by treatment with PG synthesis 
blockers, but effects on survival are minimal; 3.) species variations con¬ 
found efforts to construct a unified pathophysiologic theory of sepsis. 
Data concerning the therapeutic use of PG infusion during endotoxin 
shock have been similarly inconclusive. Raflo and associates (93, 212) re¬ 
ported improved hemodynamics and increased survival of dogs which received 
intravenous infusions of PGE-, or PGF0 followina endotoxin administration. 
Sorrells et aj_. (243) noted hemodynamic improvements in dogs pretreated with 
9.5 yg PGE-j infused over 10 minutes prior to endotoxin injection. The num¬ 
bers of animals used in these studies, however, were small and it is there¬ 
fore, unclear whether or not these results may be regarded as significant. 
‘ 
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Moveover, other investigators have failed to observe improvements in 
survival or in physiologic parameters following PG infusion during endotoxin 
shock. They have used several different infusion schedules: PGE-| (1 yg/kg/min 
for 2 hours) in dogs given an LDgg injection of endotoxin (165); using PGE-j 
(2 yg/kg/min for 4 hours) in dogs (235); or using PGA^, PGE^, or PGFg^ 
(1 yg/kg/min) following LD^q endotoxin administration to rabbits (79). Of 
note, however, is Flynn's observation (79) that arachadonic acid infusion 
(15 yg/kg/min) did improve survival following endotoxin shock. This suggests 
that a different PG, such as an endoperoxide, PGIgj or TXAg, may play a pro¬ 
tective role during endotoxemia. A1ternatively, this finding might suggest 
that the availability of AA for PG synthesis is a limiting factor, so that in¬ 
fusion of AA allows tissues to synthesize PGs as required. 
Thus, endotoxin shock studies reveal a confusing picture in relation to 
PGs. The body of evidence suggests that levels of PGE and PGF^ are altered 
during endotoxemia; yet whether this represents increased synthesis or de¬ 
creased degradation is not known. Most studies using PG synthesis inhibitors 
have implied that PGs play a role in the acute hypersensitivity reaction to 
endotoxin administration; the effects of PGs during endotoxic shock are, how¬ 
ever, unclear. Studies intended to define a role of PGs by infusion of dif¬ 
ferent PGs have yielded contradictory information, although the most recent 
of these studies implies that PGs play a protective role in an indeterminate 
manner. 
Finally, as has been noted earlier, the significance of endotoxin shock 
in understanding the pathophysiology of clinical sepsis is unclear. Certain¬ 
ly the acute hemodynamics of endotoxin injection in laboratory animals. 
■ 
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using overwhelming doses of endotoxin, has little to do with the clinical 
observations. Thus, the role of PGs in sepsis remains unknown. 

26. 
AIM OF THE PRESENT INVESTIGATION 
Despite the large number of investigations into the possible roles of 
prostaglandins in hemorrhage and endotoxemia, there is still much debate on 
that subject. Studies on PGs during hemorrhage and endotoxin shock have not 
provided consistent results, as has been described in the previous sections, 
and frequently results have been questioned on the basis of the small num¬ 
ber of animals used. For example, although arterial PGE^ has been reported 
by many authors to be elevated during hemorrhage, there is still no clear in¬ 
dication whether altered pulmonary metabolism of circulating PGs contributes 
to this increase in arterial concentrations. There is little agreement on 
the effect of PG synthesis inhibition or of PG infusion during hemorrhage. 
Studies in endotoxin shock have shown repeatedly that PG synthesis inhibition 
abolishes the acute effects of endotoxin administration; the effect of this 
intervention (PG blockade) is unclear in the later stages of endotoxin shock. 
One of the sources of the disagreements concerning PG roles in the 
altered circulatory states of hemorrhage and sepsis may be that previous 
studies have usually used large animals, particularly dogs. Use of large 
animal models, however, may introduce variables, such as species differences, 
uncertain diets prior to studies, and so on. The use of small animals, such 
as rats, may allow more control of these variables, since genetically identi¬ 
cal animals, of the same age and sex, and on the same diet, are available in 
large numbers without undue expense. Thus, a number of biological variables 
are minimized, and numbers for adequate statistical analysis are available. 
Therefore, it would be constructive to carry out investigation concerning 
the role of PGs during hemorrhage and sepsis using a small rodent, such as 
. 
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the rat, for which reliable models are well established. The following 
questions might be then addressed: 
1. ) Are prostaglandin levels altered during hemorrhage, as assessed by 
readily available methods, such as RIA? 
2. ) Is the capacity of the pulmonary vascular bed to metabolize PGs altered 
during hemorrhage, and how might this affect circulating levels of PGs? 
3. ) Does PG synthesis inhibition by indomethacin affect the outcome follow¬ 
ing hemorrhage? 
4. ) Does infusion of PGE2 following inhibition of endogenous PG synthesis 
by indomethacin benefit survival following hemorrhage? 
5. ) Does PG synthesis inhibition affect the outcome following various stages 
of sepsis, and if so, does this direct to further studies? 
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MATERIALS AND METHODS 
Animal Models 
A. Hemorrhage Model 
1. For Measurement of Plasma Prostaglandin Levels 
Albino male rats of the Holtzman strain (Charles River, Wilmington, 
Mass.) weighing 300 to 375 gm were fasted for 16 hours prior to experiments, 
but allowed water ad libitum. Under light ether anesthesia, cannulae were 
inserted into the right femoral artery, right femoral vein, and right sub¬ 
clavian artery, using PE-50 polyethylene tubing. For studies of plasma PG 
levels only, the renal vein was also cannulated. Using electrocautery, a 
2 cm midline abdominal incision was made and the peritoneal cavity opened. 
The right iliofemoral vein was isolated and a silastic cannula (O.D., 0.037") 
was inserted and directed so that its tip lay in the left renal vein ap¬ 
proximately 6 mm from the hi 1 urn. The silastic cannula was brought out 
through the skin via a stab wound in the flank and the abdomen was closed. 
Each of the above cannulae was flushed with 250 U sodium heparin. The fe¬ 
moral artery cannula was connected to a 1.75 m length of PE-50 tubing pre¬ 
viously calibrated in mm Hg to allow constant monitoring of mean arterial 
pressure (MAP). The animals were restrained in a supine position and al¬ 
lowed to awaken. Ether was used only during cannulation, thus avoiding any 
metabolic or hemorrhagic alterations which might be incurred by circulating 
anesthetic. 
Following equilibration of blood pressure (MAP>100 mm Hg) hemorrhage 
was initiated. Initial (control) blood samples (1 to 1.5 cc) were taken 
from the subclavian artery, renal vein, and femoral vein. The subclavian 
' 
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artery cannula was then connected to a heparinized lOcc glass syringe which 
served as a blood reservoir and blood withdrawn so that MAP fell to 40 mm Hg 
within 800 seconds. Animals were maintained at this level of hypotension by 
further withdrawal or return of shed blood. Thirty or 60 minutes following 
initiation of hemorrhage a second set of samples (0.8 to 1.5 cc) was with¬ 
drawn from the above cannulae. 
2. For Studies of Pulmonary Metabolism of Prostaglandins 
In another set of experiments designed to assess pulmonary metabolism 
of PGE2 during hemorrhage the above procedure was slightly modified. Rats 
were used in groups of four and PE-50 tubing cannulae were inserted into 
the right femoral artery and vein and into the right subclavian artery. The 
subclavian cannula was lodged as close as possible to the aortic arch. Nine 
animals were subjected to hemorrhagic hypotension for 75 minutes as described 
above. The control group were prepared in exactly the same manner, i.e., 
cannulated and allowed to awaken, but were not bled. Labeled (5, 6, 8, 
11, 12, 14, 15-^H-PGE^, specific activity 130.0 mCi/ymol), which had been 
rechromatographed on silicic acid columns and dissolved on 100% ethanol, was 
injected into the femoral vein and flushed with 0.5 cc saline. The amount 
of labeled PGE^ used was approximately 1.25 yCi in 0.2 cc ethanol. Immediate- 
following injection blood was withdrawn from the subclavian artery cannula 
for 20 seconds (1 to 2 cc) and the sample quickly injected in 8 cc ice-chilled 
redistilled ethyl acetate. Thereafter rapid thoracotomy was performed and a 
small piece of lung tissue taken from the right lower lobe using stainless 
steel tongs which were pre-cooled in liquid nitrogen. 
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3. For Studies of Survival following Pharmacologic Manipulations 
The hemorrhage model was modified for a set of experiments designed to 
assess survival following pharmacologic manipulations of PGs during hemor¬ 
rhage. Animals were cannulated (right femoral artery and vein and left 
femoral artery), connected to a manometer as previously described, restrained 
in a supine position, and allowed to awaken. Animals were studied in groups 
of four so that animals with and without indomethacin and/or PGE^ treatment 
during hemorrhage could be run concurrently. In the first set of rats the 
survival following hemorrhage in animals treated with indomethacin was com¬ 
pared with survival in animals receiving vehicle alone. Fifteen to 30 min¬ 
utes prior to bleeding animals were pretreated with indomethacin (5 mg/kg); 
control animals received the equivalent volume of vehicle (20 mM phosphate 
buffered saline, pH 7.6). In the second set of experiments survival follow¬ 
ing hemorrhage was compared between two groups: those which received indo¬ 
methacin pretreatment and PGE2 infusion; and those which received vehicle 
alone. One group of animals served as indomethacin-controls. These animals 
received indomethacin pretreatment and infusion, but were not hemorrhaged. 
Fifteen to 30 minutes following pretreatment with indomethacin (5 mg/kg) 
or buffer, hemorrhage was initiated by bleeding the animals into a 10 cc 
heparinized glass syringe. Simultaneously all animals received one of the 
following four solutions, infused via a Harvard infusion pump at a rate of 
0.01 ml/min during the entire 75 minute course of hemorrhage: 
Control 1 (vehicle only) 20 mM phosphate buffered saline 
Indomethacin treatment 3.5 mg/kg/hr indo. in buffered saline 
Control 2 (vehicles only) 3% absolute ethanol in saline 
Indo. + PGE2 treatment 0.1 yg/kg/min PGE2 in saline. 
Aliquots of PGE2 were made up just prior to use and the infusion solution was 
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replaced with freshly diluted solution after 45 minutes to assure infusion 
of chemically unaltered PGE2. The corresponding control group received 3% 
ethanol to match the ethanol concentration given to PGE^-infused rats. 
Animals were bled to 40 mm Hg and maintained for 75 minutes at that 
hypotension. After 75 minutes the remaining shed blood was reinfused and 
the cannulae were removed. Animals were returned to their cages and allowed 
food and water ad 1ibiturn. Survival was assessed over a period of 48 hours. 
Animals which died were examined at autopsy for evidence of gastrointestinal 
bleeding. 
4, For Studies of Blood Gases during Hemorrhage 
A small number of animals were used to determine arterial blood gases 
during hemorrhage. Animals were prepared as for survival studies and pre¬ 
treated with indomethacin (5 mg/kg) or vehicle. Infusion of indomethacin 
or buffer as described above was started at the initiation of hemorrhage. 
An initial sample of blood (1.5 cc) was withdrawn from the femoral artery 
for blood gas analysis. After maintenance of 40 mm Hg hypotension for 75 
minutes, a second arterial blood sample (1.5 cc) was withdrawn and analyzed 
for blood gases. 
B. Sepsis model 
Sepsis was induced by cecal ligation and puncture according to the 
model previously described (272). Albino male Holtzman rats (300 to 375 gm) 
were fasted for 24 hours prior to the study. Animals were studied in groups 
of four so that control and treatment data could be obtained simultaneously. 
Following the initiation of food deprivation, animals were given indometha¬ 
cin (1 mg/kg) dissolved in olive oil or the equivalent volume of oil alone 
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subcutaneously twice a day for a total of three days. Twenty-four hours 
after the initiation of fasting and treatment, animals were given a bolus 
of indomethacin (4 mg/kg) or the equivalent volume of phosphate buffered 
saline intraperitoneally. After thirty minutes animals were anesthetized 
lightly and a 2 cm midline abdominal incision made. The cecum was isolated 
and ligated with a 5-0 silk without producing intestinal obstruction. The 
cecum was punctured twice with an 18 gauge needle, placed back into the 
peritoneal cavity, and the abdominal wound closed in layers. Animals were 
then given normal saline (30 cc/kg) subcutaneously and returned to their 
cages. Food and water was withheld for an additional 48 hours. 
Ten or sixteen hours later (corresponding to early or late sepsis, 
respectively), animals were again anesthetized and PE-50 cannulae in¬ 
serted into the right femoral artery and vein. The arterial line was con¬ 
nected to a manometer and only animals with MAP>_90 mm Hg were used and in¬ 
cluded in the study. The abdomen was then reopened and the cecum excised. 
The peritoneal cavity was thoroughly lavaged with warm saline and the abdomi¬ 
nal incision closed. Following removal of the cecum, animals were treated with 
indomethacin (6.7 mg/kg) or buffer intravenously and given intravenous saline 
(15 cc/kg) over 3 to 5 minutes. Thereafter, rats were returned to their 
cages. Food and water were still withheld. Over the succeeding 36 hours 
animals were given saline subcutaneously, as well as subcutaneous indometha¬ 
cin or oil vehicle, according to the schedule shown in Figure 2. There¬ 
after, animals were allowed food and water ad libitum. Survival was assessed 
over the interval of five days following cecum removal. Animals which died 
were examined for evidence of gastrointestinal hemorrhage. 
• 
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FIGURE 2 33. 
PROTOCOLS FOR SEPSIS SURVIVAL STUDIES 
Day Time Early Sepsis Late Sepsis 
1 4:00 pm -Indo 1 mg/kg or oil SQ- 
-Food withheld- 
0 8:00 am Indo 1 mg/kg or oil SQ 
4:30 pm Indo 1 mg/kg or oil SQ Indo 4 mg/kg or vehicle IP 
5:00 pm Cecal ligation and Puncture 
Saline 30 cc/kg SQ 
Indo 1 mg/kg or oil SQ 
10:30 pm 
11:00 pm 
1 9:00 am 
Indo 4 mg/kg or vehicle IP 
Cecal Ligation and Puncture 
Saline 30/cc/kg SQ 
Indo 1 mg/kg or oil SQ 
-Monitor MAP- 
-Excision of Cecum- 
-Lavage of Peritoneum- 
Indo 6.7 mg/kq or vehicle IV 
-Saline 12 cc/kg IV- 
— Indo 1 mg/kg or oil SQ— 
4:00 pm -Saline 15 cc/kg SQ-- 
--—Indo 1 mg/kg or oil SQ 
2 8:30 am -Saline 22.5 cc/kg SQ- 
Indo 1 mg/kg or oil SO 
6 9:00 am Assess Survival 
Legend: Indo = Indomethacin 
Vehicle = 20 mM phosphate buffered saline 
SQ = subcutaneous 
IP = intraperitoneally 





A. Preparation of Samples for Assay of Prostaglandins 
The blood samples were placed immediately on ice and centrifuged, 
usually within 5 minutes,at 4° C. in a Beckman J-21B centrifuge. The plas¬ 
ma supernatant was removed and frozen at -80° C. Plasma samples were 
assayed for PGs within 10 days. 
B. Extraction and Measurement of Plasma Prostaglandins 
Measurement of plasma PGs was done by radioimmunoassay (RIA) according 
to the method of Jaffe and Behrman(126). 
The frozen samples were thawed to room temperature and PGs extracted 
with redistilled ethyl acetate at a pH of approximately 4.5. Samples were 
centrifuged at 3000 rpm for 10 minutes at 4° C. and the supernatant re¬ 
moved and evaporated under air at room temperature. The residue was dis¬ 
solved in benzene:ethyl acetate:methanol (60:40:2). 
A column chromatography procedure was used to separate PGE and PG- 
Fifteen cm glass burets containing 0.5 gm silicic acid were set up. Sam¬ 
ples were placed onto the columns and elution of PGs carried out using ben- 
zene:ethyl acetate:methanol mixtures of increasing methanol concentration. 
This procedure has been shown previously to give excellent separation of 
PGs (35). 
Radioimmunoassay was carried out using standard techniques (126). 
PGE and assays were done simultaneously, using the fractions separated 
by chromatography. Column eluents were evaporated at room temperature, the 
PGF fraction under air and the PGE fraction under nitrogen. The residues 




were placed in test tubes and evaporated under air (PGF) or nitrogen (PGE) 
at room temperature. Anti-sera were obtained from goats which had been in¬ 
jected with PGE or PGF conjugated to bovine serum albumen by carbodiimide. 
Antisera and labelled PGE or PGF2a were added to assay tubes. Known standards 
of each PG were run in triplicate concurrently, using concentrations of 0.1 
to 20 ng/ml. Mixtures of antiserum, labelled PG, and samples/standards were 
allowed to equilibrate at 4° C. over a two hour interval. Antigen-antibody 
complexes were precipated using charcoal-coated dextran and samples centri¬ 
fuged at 2500 rpm for 5 minutes at 4° C. Supernatant free PGs were decanted 
into scintillation vials and 10 cc Formula-963 scintillation fluid added. 
Samples were counted for 10 minutes on a Packard Tri-carb liquid scintilla¬ 
tion counter. Concentrations of unlabelled PG in rat plasma samples were 
calculated from the curves of known standards. 
C. Thin Layer Chromatographic Separation of Prostaglandin Metabolites 
A number of investigators have used several thin layer chromatographic 
systems (TLC) to separate the primary pulmonary metabolic degradation pro¬ 
ducts of the PGs (10, 99, 213, 244). For the in vivo pulmonary metabolism 
study described below, it was essential to be able to separate quantitative¬ 
ly the PGE2 metabolites. To determine the best system for separation four 
solvent systems were tested. 
Prostaglandin E2 and its three principal pulmonary metabolites, 
13,14-dihydro-PGE2, 15-keto-PGE and 13,14-dihydro,15-keto-PGE2, were 
dissolved in absolute ethanol and stored under nitrogen at -80° C. TLC 
of these four compounds was performed using 250 y Silica Gel G plates. 
Along a line 1 cm from the lower edge of the plate 300-500 yg of each 
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compound was spotted. The plates were dried under room air. Four solvent 
systems were made up: 
1. Ethyl acetate:water;2,2,4-trimethyTpentane,;acetic acid 110:100:20:1 
2. Benzene:dioxane:acetic acid 20:10:1 
3. Benzene:dioxane:acetic acid 66:33:1 
4. Benzene:dioxane:acetic acid 40:10:1. 
Solvents were placed in a chromatography tank to a depth of approximately 0.5 
cm and the plate placed into the tank. Plates were left in the solvent un¬ 
til the solvent edge had run 12-13 cm, which required 70-90 minutes. Fol¬ 
lowing this, the plates were removed, air dried, sprayed with 3I phosphomo- 
lybdic acid, and heated gently on a warm hot plate for 10 minutes. Spots 
corresponding to each compound were identified and values calculated as 
(distance traveled by compound) / (distance traveled by solvent front). 
D. Preparation of Blood and Lung Samples for Metabolism Studies. 
Blood samples, which had been injected into ice-chilled ethyl acetate 
immediately after withdrawal, were centrifuged at 4° C. at 6000 rpm for 15 
minutes in a Bedkman J-21B Centrifuge and the supernatant removed. To 
assess recovery of labeled PGE^ an aliquot of 0.1 cc was taken for counting. 
The remainder of the sample was evaporated under nitrogen at room tempera¬ 
ture and redissolved in 0.2 cc absolute ethanol. 
Lung samples were stored at -32° C. until a sufficient number were 
collected within 24 hours. Samples were weighed and homogenized quickly in 
1 cc trichloracetic acid (10%)-HC1 (0.1 N). To each homogenate 8 cc ice- 
chilled redistilled ethyl acetate was added. Samples were centrifuged at 
6000 rpm for 15 minutes at 4° C. and an aliquot of 0.1 cc taken to test 
. 
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recovery. The remainder was evaporated under nitrogen at room temperature 
and redissolved in 0.2 cc absolute ethanol. 
Recovery samples were evaporated under room air at room temperature and 
the residue dissolved in 0.1 cc absolute ethanol. To this solution 10 cc 
Formula-963 scintillation fluid was added and the recovery samples counted 
for 10 minutes on a Packard Tricarb Liquid Scintillation Counter. 
E. Separation of Labeled Prostaglandins for Metabolism Studies 
Ethanol dissolved residues (from extraction of plasma containing labeled 
PGE^ and metabolites) were subjected to TLC, using solvent system 4 and 250 y 
Silica Gel G plates. Mixtures of standards containing 350 yg of each 
metabolite and 350 yg of PGE2 were spotted at two points on each plate 1 cm 
from the lower edge of the plate. Four samples were spotted in a volume of 
0.15 cc each to run in parallel with the known standards. Spots were dried 
under air. Plates were run as described above, air dried at room tempera¬ 
ture, and the two sections of the plate containing standards sprayed with 
3% phosphomolybdic acid Upon gentle heating the standards were identified 
and the areas on the plate containing labeled compound which corresponded 
with standard compounds thereby identified. These areas were removed end 
eluted into scintillation vials using methanol, which was evaporated under 
air and the residue redissolved in 0.1 cc absolute ethanol. To each vial 
10 cc Formula-963 was added and samples counted on a Packard Tri-Carb Liquid 
Scintillation Counter for 10 minutes. 
To assess the purity of the injected tritiated PGE^, as well as to check 
the validity ot separation achieved by TLC, a small aliquot of each lot of 
3 




presented have been corrected for background and for initial impurity. 
Fractional amounts of each metabolite have been calculated as M./(Mg + M-j + 
Mg + Mg), where Mg_g represent the corrected cpm of native PGEg, 13,14-di- 
hydro-PGEg, 15-keto-PGEg, and 13,14-dihydro,15-keto-PGEg, respectively. 
F. Blood Gas Measurement 
Samples of arterial blood for blood gas analysis were taken for immedi¬ 
ate analysis on an IL Blood Gas Analyzer (Model 213). Values reported are 
the mean of three determinations on each sample. 
Statistical Methods 
All data have been analyzed according to standard statistical technique. 
Statistical comparison of mean values has been carried out using a two-tailed 
Student's t test. Survival data have been compared using a two-tailed Chi- 
square analysis. Differences are considered statistically significant for 
values of p<0.05. 
Materials 
Unlabelled prostaglandin Eg and its three metabolites were the generous 
gift of Dr. John Pike (Upjohn Company, Kalamazoo, Mich.). Tritiated PGEg 
(5,6,8,11,12,14,15- H-PGEg) was purchased from New England Nuclear (Boston, 
Mass.). Tritiated PGFg^ (5,6,8,11,12,14,15-^H-PGFg) for RIA was also ob¬ 
tained from New England Nuclear. Indomethacin was the generous gift of 
Merck, Sharp, and Dohme (Rahway, N.J.) and Dr. H.R. Behrman. 
Tubing for cannulation consisted of PE-50 polyethylene tubing (Clay 
Adams, Parsippany, N.J.) and Silastic tubing (Dow Corning, Midland, Mich.). 

39. 
Equipment for TLC included Silica Gel G plates, obtained from New Eng¬ 
land Nuclear, as was Formula-963 scintillation fluid. All reagents used in 
analyses were of analytic grade or better. Ethyl acetate was redistilled 




Plasma Prostaglandin Levels during Hemorrhage 
Plasma concentrations of PGE and of PGF0 obtained from the subclavian 
artery, femoral vein, and from the renal vein of 10 rats both at the initi¬ 
ation of hemorrhage and 30 or 60 minutes after the initiation of hemorrhage 
are shown in Tables 1 and 2. It is apparent from these tables that PG levels 
vary dramatically, irrespective of source and of time obtained in relation to 
hemorrhage. The initial PGE levels in renal vein plasma varied from 0.59 to 
26.3 ng/ml; in femoral vein from 1.5 to 61.5 ng/ml; and in subclavian artery 
from 0.76 to 51.3 ng/ml. Similar variations in PG levels were observed in 
samples taken from these sites following 30 or 60 minutes of hemorrhage. Like¬ 
wise, values for PGF^ concentration in plasma varied markedly. 
Mean PGE and PGF0 levels are presented in Table 3. It is clear from 
this table that there are no significant increases or decreases in either 
PGE or PGF^ levels at various intervals during hemorrhage. Although mean 
PG levels at 60 minutes are lower than mean initial values in both subclavian 
artery and femoral vein samples, these decreases are misleading, as is evi¬ 
dent from values reported in Tables 1 and 2. Moreover, the numbers of ani¬ 
mals reported are small. The absence of significant changes is not surprising 
in the face of the large variations in individual values. 

TABLE 1 41 . 
PLASMA PROSTAGLANDIN E2 LEVELS DURING HEMORRHAGE 
PGE (ng/ml) and relative PGE 
Animal Source Initial PGE 30 min. 60 min. 
SA 25.3 14.4 (0.57) 
1 FV bl .5* 15.1 (0.25) 
RV 24.3 - 
SA 26.6 6.5 (0.22) 
2 FV 19.2 10.8 (0.56) 
RV 5.2 10.8 (2.01) 
SA 51.3* 10.1 (0.20) 
3 FV 21.1 - 
RV 22.4 - 
SA 5.95 4.90 (0.84) 
4 FV 8.48 7.50 (0.88) 
RV 5.89 11.34 (1.92) 
SA 6.68 6.74 (1.01) 
5 FV 7.24 9.08 (1.25) 
RV 5.80 8.17 (1.41) 
SA 4.98 7.48 (1.57) 
6 FV 5.77 6.83 (1.18) 
FV 1 .55 1.66 (1.07) 
7 RV 1.60 2.57 (1.61) 
SA 0.74 0.70 (0.95) 
8 FV 4.13 0.94 (0.23) 
RV 10.93 4.40 (0.40) 
SA 3.44 2.02 (0.59) 
9 FV 8.68 - 
10 RV 0.59 1.43 (2.42) 
* Values determined from only one aliquot, rather than as the mean 
of three. 
Measurement of PGE-equivalent by RIA of plasma samples obtained from 
subclavian artery (SA), femoral vein (FV), and renal vein (RV) at dif¬ 
ferent times in relation to hemorrhage. Relative values are ratios of 
PGE levels during shock divided by initial values and are given in pa¬ 




PLASMA PROSTAGLANDIN F 
2a 
LEVELS DURING HEMORRHAGE 
PGF0_. (ng/ml) and relative PGF0„. 
2_ Oi -E_U, l— cx
Animal Source Initial PGF 30 min 60 min 
SA 17.6 14.9 (0.85) 
1 FV 12.0 10.6 (0.88) 
R V 12.0 - 
SA 13.0 11.0 (0.85) 
2 FV 8.8 6.4 (0.73) 
R V 1.5 4.7 (3.18) 
SA 12.5 4.6 (0.37) 
3 FV 9.8 - 
RV 5.3 - 
FV 0.89 0.88 (0.99) 
7 RV 0.73 0.96 (1.32) 
SA 0.68 0.61 (0.90) 
8 FV 0.93 0.69 (0.74) 
RV 1 .26 1.73 (1.37) 
SA 0.78 1.30 (1.67) 
9 FV 1.12 1.14 (1.02) 
10 RV 0.71 0.69 (0.97) 
PIasma PGF2a levels as measured by RIA from samples obtained from sub- 
cl avian artery (SA) , femoral vein (FV), and renal vein (RV) at dif- 
ferent times in relation to hemorrhage. Relative values are ratios of 
PGF2a levels during hemorrhage divided by initial values and are pre¬ 




MEAN PLASMA PROSTAGLANDIN LEVELS DURING HEMORRHAGE 
PG In nq/ml 
PG Source Initial 30 min 60 min 
SA 10.4 ± 4.1 7.3 ± 3.6 5.0 ± 1.5 
E FV 11.0 ± 2.1 12.9 ± 2.1 5.2 ± 1.6 
RV 5.8 ± 1.5 6.1 ± 4.7 6.8 ± 1.9 
SA 8.6 ± 3.5 10.2 ± 3.0 1.0 ± 0.4 
Fo FV 4.6 ± 2.4 6.1 ± 2.7 0.8 ± 0.1 ca 
RV 1.1 ± 0.2 2.7 ± 2.0 1.4 ± 0.3 
Plasma prostaglandin E and F2a levels as determined by RIA of sam¬ 
ples obtained from subclavian artery (SA), femoral vein (FV), and 
renal vein (RV). Values presented are averaged data from 7 to 10 
rats subjected to hemorrhage for 30 or 60 minutes. Values given 
are mean ± SEM. 

44. 
Thin Layer Chromatography of Prostaglandin Eq and its Pulmonary Metabolites 
Four solvent systems were tested using PGE2 and its three major pulmonary 
metabolites on silica gel G plates. values are presented in Table 4. On 
the basis of this data solvent system 4 was chosen for use in studies using 
labeled PGE2> since it gave complete separation of all four compounds with 
zones between neighboring compounds. This system, therefore, offered the 




THIN LAYER CHROMATOGRAPHY OF PROSTAGLANDIN E2 
AND ITS PULMONARY METABOLITES ON SILICA GEL G 
USING FOUR SOLVENT SYSTEMS 
Solvent System PGE:. M1 M^ Mi 
1. Ethyl acetate:water: 
isooctane:acetic acid 0.82 0.76 0.78 0.84 
110:100:20:10 
2. Benzene:dioxane: 0.41 0.60- 0.65 0.73- 
acetic acid 20:10:1 0.47 0.62 0.72 0.76 
3. Benzene:dioxane: 0.34- 0.49- 0.67- 0.70- 
acetic acid 66:33:1 0.43 0.52 0.72 0.73 
4. Benzene:dioxane: 0.15- 0.26- 0.42- 0.49- 
acetic acid 40:10:1 0.21 0.28 0.47 0.54 
Thir i layer chromatographic separation of known : standard PGE2 and I its 
three primary metabolites on 250 y Silica Gel G using different sol - 
vent systems. Compounds are: 
PGE2 = Prostaglandin E2 
Mx = 13,14-dihydro-PGE2 
M2 = 15-keto-PGE2 
M3 = 13,14-dihydro,15-keto-PGE2 

46. 
Pulmonary Metabolism of Prostaglandin Eg during Hemorrhage 
Prior to infusion of labelled PGE2, its purity was assessed by TLC. The 
first lot, which was used in 12 of the 15 experimental animals, showed 93.2% 
PGEg with the predominant impurity being M-j (13,14-dihydro-PGEg, 5.5%). The 
second lot was shown to contain 84.5% ^H-PGEg, 6.7% M-j , 3.0% Mg (15-keto-PGEg), 
and 5.8% Mg (13,14-dihydro,15-keto-PGEg). The impurities do not necessarily 
represent PGE metabolites per se, but might be impurities which simply have 
the same as the metabolites. The results presented below, however, have 
been calculated with these impurities taken into account. 
Studies of metabolites in arterial blood showed a significant increase 
in the amount of unmetabolized PGEg after 75 minutes of hemorrhage as com¬ 
pared with control animals. Fractional counts of PGEg and its three metabo¬ 
lites are given in Table 5 and mean values in arterial blood and lung tissue 
are given in Table 6. The increase in unmetabolized PGEg from 20.7% to 
57.4% is statistically significant (t= 3.06, p<0.01). Most of the decreased 
metabolism was accounted for by decreased oxidation to Mg (from 38.9% to 17.3%, 
t=2.44, p<0.05) and, to a lesser degree, to Mg (35.9% to 19.5%, t=1.34, 
p<0.10). 
There was virtually no difference in relative amounts of metabolites in 
lung tissue, as is shown in Table 6. Recovery of label in the lung tissue 
was greater, however, in hemorrhaged animals (32.9 + 5.6 cpm/mg lung tissue) 
than in controls (5.2 + 1.2 cpm/mg lung tissue). 

TABLE 5 47. 
IN VIVO METABOLISM OF PROSTAGLANDIN E2 DURING HEMORRHAGE 






0.204 0.109 0.483 0.204 
0.162 0.060 0.748 0.030 
0.469 0.090 0.248 0.193 
0.122 0.040 0.150 0.688 
0.191 0.007 0.423 0.379 
0.093 0.041 0.263 0.602 
FOLLOWING 75 MIN 
HEMORRHAGE 
0.450 0.074 0.358 0. .118 
0.925 0.039 0.023 0. .008 
0.409 0.085 0.182 0. .324 
0.314 0.076 0.428 0. ,182 
0.465 0.075 0.078 0. .382 
0.469 0.098 0.127 0. .306 
0.517 0.027 0.203 0. .253 
0.663 0.025 0.143 0. .169 
0.957 0.022 0.010 0. ,011 
Relative in vivo concentrations of PGE2 and its three primary metabo¬ 
lites in arterial blood 5 to 20 seconds following bolus intravenous in¬ 
jection of labelled PGE2 in 9 animals subjected to hemorrhage for 75 
minutes and 6 unhemorrhaged control animals. Numbers represent ratio 
of counts associated with each metabolite to total counts obtained, fol¬ 
lowing separation of compounds by TLC. Compounds: 
PGE2 = Prostaglandin E2 
Mi = 13,14-dihydro-PGE2 
M2 = 15-keto-PGE2 




AVERAGE IN VIVO METABOLISM OF PROSTAGLANDIN E2 DURING HEMORRHAGE 
Fractional Concentration of PGEq and Metabolites 
BLOOD LUNG 
Compound Control Hemorrhaged Control Hemorrhaged 
pge2 0.207 + 0.055 0.574 + 0.090* 0.267 0.284 
mi 
0.058 + 0.015 0.058 + 0.010 0.204 0.202 
M2 0.389 + 0.088 0.173 + 0.043** 0.207 0.176 
M3 
0.349 + 0.121 0.195 + 0.019 0.322 0.336 
* p < O.Ol compared with control 
** p < 0.05 compared with control 
Average relative concentration of PGE2 and its metabolites in 
arterial blood and lung tissue following injection of labelled 
PGE2 into 9 rats subjected to hemorrhage for 75 minutes and 6 
unhemorrhaged rats. Numbers represent ratios of counts asso¬ 
ciated with each metabolite to total counts measured, following 
separation of compounds by TLC. Values here represent mean + 
SEM. 
PGE2 = Prostaglandin E2 
M2 = 13,14-dihydro-PGE2 
M2 = 15-keto-PGE2 




Survival following Hemorrhage 
A total of 92 rats were used for this study. Of these, 72 rats are in¬ 
cluded in the calculation of survival rates following hemorrhage. An addi¬ 
tional 16 were excluded because of technical failures, such as excessive 
blood loss during decannulation (n=5) or because they died during the hemor¬ 
rhage procedure (n=ll). All of the four unhemorrhaged indomethacin controls 
survived. 
As shown in Table 7, the survival rate following hemorrhage in control 
rats (receiving buffer as pretreatment and infusion) was 68.8% (11/16). The 
survival rate in animals which received indomethacin pretreatment and infusion 
was 29.8% (5/17), which is significantly less than controls (x' =5.10, p<.025). 
Eight animals which were receiving indomethacin died before the completion 
of the 75 minute hemorrhage period. These animals did not appear to be sub¬ 
jected to more severe hypotensive stress than other animals. Since no con¬ 
trol animals died during the hemorrhage interval and death during hemorrhage 
has been extremely rare in previous studies in this laboratory, the death of 
8 indomethacin treated animals reported above would appear to be related to 
the adverse effect of indomethacin. Indeed, the survival rate of animals 
treated with indomethacin, including the 8 which died during hemorrhage was 
20% (5/25), which is significantly less than controls (x2=9.74 5 p<0.001). 
There were no differences in the severity of hemorrhage in the groups 
of animals which did or did not receive indomethacin, as shown by shed volume 
(10.7 vs 10.3 cc) or amount of shed blood returned during 75 minutes to main¬ 
tain the animals at 40 mm Hg (29.2% vs 24.5% of total amount shed). Autopsy 




In another set of experiments PGE2 was infused during hemorrhage into 
animals which had previously received the PG synthesis blocker indomethacin. 
The purpose of this experiment was to determine whether selective replace¬ 
ment of PGE2 during hemorrhage would be beneficial and whether blockade of 
PGE2 synthesis was responsible for the decreased survival in animals treat¬ 
ed with indomethacin. The control animals in this group received buffer pre¬ 
treatment and a 3% ethanol infusion to correspond with the ethanol concentra¬ 
tion in treated animals. The survival rate of these control animals was 
55.6% (5/9) which is not significantly different from control animals which 
did not receive ethanol. Animals given indomethacin pretreatment to block 
de novo PG synthesis and selective infusion of PGE2 at peak physiologic rates 
had a survival rate of 42.1% (8/19), which is not significantly different 
from controls or from animals which received indomethacin alone. Three ani¬ 
mals which received indomethacin and PGE2 died during the 75 minute hemor¬ 
rhage period. If these animals are included in the survival data, total 
survival was 36.4% (18/22), which is significantly different from controls 
(x2=3..88. p<0.05) but not from animals treated with indomethacin alone. These 
results indicate that infusion of PGE2 alone following blockade of endogenous 




SURVIVAL FOLLOWING HEMORRHAGE 
Died during Overall 
Treatment Survived Died % Survival Hemorrhage % Survival 
Buffer pretreatment 
and infusion 11 5 68.8 0 68.8 
Indomethacin pretreatment 
and infusion 5 12 29.4a 8 20.0b 
Buffer pretreatment and 
3% ethanol infusion 5 4 55.6 0 55.6 
Indomethacin pretreatment 
and PGE2 infusion 8 11 42.1 3 36.4C 
a. p < 0.025 compared with control. 
b. p < 0.001 compared with control. 
c. p < 0.05 compared with control. 
Survival data in 71 rats subjected to 75 minutes of hemorrhagic hypoten¬ 
sion (MAP = 40 mm Hg) using different treatment protocols. Animals were 
pretreated with indomethacin (5 mg/kg) or buffer vehicle intravenously 
15-30 minutes prior to hemorrhage and infused at 0.01 ml/min with buffer, 
indomethacin (3.5 mg/kg/hr), 3% ethanol in saline, or prostaglandin E2 
(100 ng/kg/min) throughout the 75 minute period of hemorrhage. Survival 
was assessed at 48 hours after hemorrhage. Overall percent of survival 




Blood Gas Analysis during Hemorrhage in Relation to Indomethacin 
Out of the four animals used in this study, one served as a control and 
was subjected to hemorrhage following buffer pretreatment and with buffer 
infusion. The other three rats were pretreated with indomethacin and in¬ 
fused with indomethacin during hemorrhage. Blood gases are presented in 
Table 8. There are no differences between the arterial blood gas values of 
the two groups of animals studied. 
. 
TABLE 8 53 
BLOOD GAS STUDIES DURING HEMORRHAGE 
After 75 min 
Animal Treatment Parameter Initial Hemorrhage 
\ 128 108 
1 Indomethacin P rco2 19 16 
pH 7.54 7.28 
% 80 120 
2 Indomethacin p 
rC02 
28 20 
PH 7.55 7.40 
P°2 
98 120 
3 Indomethacin P 
kC02 
36 23 










pH 7.52 7.34 
P°2 
85 120 
4 Buffer pco2 33 20 
pH 7.55 7.26 
Comparison of arterial blood gas values in 3 rats given indomethacin 
(5 mg/kg) pretreatment and an infusion of indomethacin ( [3.5 mg/kg/hr) 




Survival Following Sepsis 
Sepsis was produced by cecal ligation and puncture followed by excision 
of the necrotic septic focus after 10 hours (early sepsis) or 16 hours (late 
sepsis). 
As shown in Table 9, the survival rate of late septic rats which were 
not treated with indomethacin was 30.8% (4/13). This is consistent with the 
survival rate reported previously using this model (272). Late septic rats 
which were treated with indomethacin had a survival rate of 23.1% (3/13). 
There is, thus, no significant difference in survival in late septic rats be¬ 
tween the animals which did receive indomethacin and those which did not. 
The survival rate of early septic rats not treated with indomethacin 
was 83.3% (10/12). Treatment with indomethacin in another group of early 
septic rats resulted in a survival rate of 25% (3/12), which is significantly 
less than the control group (x2=8.22, p<0.005). 
Autopsy of dead animals showed no evidence of gastrointestinal bleeding 
in any animals. Diarrhea, a commonly observed phenomenon in septic rats, 





SURVIVAL FOLLOWING SEPSIS 
Survived Dead % Survival 
EARLY SEPSIS 
Control 10 2 83.3 
Indomethacin 
Treatment 3 9 25.0 * 
LATE SEPSIS 
Control 4 9 30.8 
Indomethacin 
Treatment 3 10 23.1 
* p<0.005 compared with control. 
Five day survival data in 50 rats subjected to sepsis in¬ 
duced by cecal ligation and puncture. After 10 or 15 
hours (early or late sepsis) the cecum was removed. Ani¬ 
mals received indomethacin (1 mg/kg) or oil vehicle twice 
daily for 3 days beginning 24 hours prior to ligation 
plus indomethacin (4 mg/kg) or bugger intraperitoneally 
30 minutes prior to ligation plus indomethacin (5 mg/kg) 
or buffer intravenously following excision of the cecum. 




1. Hemorrhage and Prostaglandins 
In attempting to assess possible roles for PGs during hemorrhage, a 
series of experiments were undertaken using a model of hemorrhagic hypo¬ 
tension in the rat (40). The specific studies which were conducted in¬ 
clude: 1.) measurement of plasma PG levels at various time intervals af¬ 
ter the initiation of hemorrhage; 2.) determination of in vivo single pass 
pulmonary PGE^ metabolism after 75 minutes of hemorrhage; and 3.) assess¬ 
ment of survival after 75 minute hemorrhage in rats treated with indometha- 
cin and with indomethacin-PGE2 combination. The results of these experiments 
indicate that PGs probably play an important protective role during hemor¬ 
rhagic hypotension. 
A. Measurement of Plasma Prostaglandin Levels during Hemorrhage 
In one set of experiments the rat model was adapted for measurement of 
plasma PGs in blood samples from the subclavian artery, femoral vein, and 
renal vein, using RIA. The result of this investigation was that no altera¬ 
tions in the levels of PGE or of PGF0 could be demonstrated after 30 or 60 
minutes of hemorrhage. From these data (presented in Tables 1-3) the fol¬ 
lowing conclusions could be drawn: 1.) there was a large variation in PG 
levels during hemorrhage irrespective of time or site of sampling; and 
2. ) that there were no patterns either in absolute mean values or in the 
relative concentrations of the PGs during hemorrhage. Thus, it appears that 
no conclusions regarding the roles of PG during hemorrhage in the rat can be 
drawn on the basis of these data. 
■ 
57. 
The large variation in both PGE (0.53 to 61.3 ng/ml) and PGF2a (0.61 to 
17.6 ng/ml) is evident from Tables 1 and 2. It is also apparent from these 
Tables that PG levels in the first animals studied were higher than in sub¬ 
sequent animals. Although data were collected from three groups of animals 
studied on separate occasions (i.e., animals 1-3, 4-6, and 7-10), no changes 
in techniques or reagents were made. Moreover, RIA of a standard plasma pool 
was carried out concurrently with sample assays and revealed only small vari¬ 
ations, indicating that the variations in the levels of experimental samples 
were not introduced by human error. There are several other possible ex¬ 
planations for the large variation in PG levels which was observed. These 
factors include: 1.) uncontrolled and variable synthesis of PGs by plasma 
elements during or immediately after withdrawal; 2.) alterations induced 
by freezing and thawing; 3.) errors introduced by measuring small amounts 
of PG in very small volumes of plasma; 4.) variation inherent in the tech¬ 
nique of RIA; 5.) spurious PG synthesis associated with surgical trauma or 
with animal struggling. Each of these possibilities is discussed below. 
It is possible that synthesis of PGs occurred in sample blood or plas¬ 
ma after withdrawal, thereby altering values obtained by RIA. Platelets are 
known to produce PGsin large quantities (88) and might be the source of spuri¬ 
ous PG synthesis. This might have occurred in spite of heparinization and 
rapid centrifugation at 4° C, Thus, this is certainly a possibility. 
Freezing and thawing has been reported to cause alterations in measured 
PGs (126), presumably by destruction of PGs. In general, however, altera¬ 
tions have not been documented until 3 weeks of freezing. 
' 
58. 
In the studies of PG levels reported here, the volumes of plasma which 
were used for RIA were very small (0.35 to 0.80 ml), due to the limitations 
inherent in the use of a small animal model, particularly for hemorrhage 
studies. The measurement of small amounts of PG (with attendant error) 
when divided by small volumes (also with associated error) yielded values 
that may be inaccurate. Indeed, previous studies of PG levels in human 
plasma have suggested that for reliable RIA a minimum of 10 ml of plasma 
is required (53). Obviously, it is not possible to obtain such a volume 
from a 350 g rat before or during hemorrhage. Previous canine studies of 
plasma PG levels during hemorrhage, using RIA (80, 132), have not specified 
plasma volumes used for assay. It would have been possible, however, to use 
volumes of 5-10 cc in these studies. 
The recent review by Granstrom (98) concerning RIA of PGs in plasma 
has indicated that this method is indeed fraught with difficulties. Errone¬ 
ous values have frequently been obtained by RIA of plasma, although the tech¬ 
nique of RIA is itself relatively reliable. The cause of the difficulties 
in plasma RIA is not known, and whether or not it is non-PG plasma elements 
which interfere with the assay has not been determined. The problems associ¬ 
ated with RIA of plasma samples may be appreciated by noting that previous 
investigators studying PGE levels during hemorrhage in dogs have de¬ 
scribed baseline PGE levels as 340 and 450 pg/ml (80, 132) when measured by 
RIA. Other investigators using different techniques have reported baseline 
values one-tenth of that value (less than 20 pg/ml by bioassay, ref. 129, 
and less than 50 pg/ml by GC-MS, ref. 84). Thus, it is possible that values 
reported in this study are falsely elevated in part because of the short¬ 





published a few months after most of the plasma PG studies reported here were 
conducted. 
Finally, the trauma of cannulation or, perhaps, withdrawal of blood might 
have caused release of PGs from tissues or vessels. In addition, animals in 
this experiment were awake at the time of the hemorrhage. This required re¬ 
straining the animals in a supine position, which caused them to struggle. The 
animals' struggling might have led to increased PG synthesis either because of 
increased sympathetic output or increased muscular activity, both of which are 
associated with increased PG synthesis (109, 139). There are, however, two 
arguments against these possible explanations of spurious PG synthesis. First, 
these effects might be expected to be observed primarily in the initial samples, 
since animals struggled most at that time. The variations in PGE and PGF^ 
levels were, on the other hand, also large after 30 or 60 minutes of hemor¬ 
rhage, indicating that struggling or initial surgical trauma are unlikely ex¬ 
planations of the variations in PG levels. The second argument is that the ini¬ 
tial samples were withdrawn from unhemorrhaged rats, in which the ability of the 
pulmonary bed to metabolize circulating PG levels would suggest that factors 
other than initial surgical trauma or awake restraint were probably responsible 
for the large variations in PG levels. The most likely factors, therefore, are 
the use of small plasma volumes, the problems associated with RIA determination 
of plasma PGs, and the possibility of platelet synthesis of PGs in samples af¬ 
ter withdrawal from animals. 
The absence of changes in plasma PG levels during hemorrhage stems in 
large part from the large variations in measured PG levels. The observed 
scatter of data makes conclusions based on mean values tenuous. Even using 

60. 
relative PG levels (concentrations after 30 or 60 minutes of hemorrhage divi¬ 
ded by initial values), no patterns are observable. This suggests that 
either alterations in rat plasma PG levels do not occur during hemorrhage 
or that these changes are masked by the wide range in individual values. 
In summary, the attempt to ascertain whether PGs play a role in hemor¬ 
rhage by direct measurement of rat plasma PGE and PGF2a levels during hemor¬ 
rhage, using RIA, did not yield meaningful results. Large variations 
in PG levels in samples taken before and during hemorrhage were observed, 
thus creating difficulty in assessing whether or not alterations in plasma 
PG levels occur during such conditions. The principal causes of the varia¬ 
tions in PG levels appear to be small sample size, use of RIA on plasma sam¬ 
ples, and possible spurious synthesis of PGs after withdrawal by blood or 
plasma constituents. 
B. Pulmonary Metabolism of Prostaglandins during Hemorrhage 
In order to study pulmonary metabolism of PGs for comparison of meta¬ 
bolic capability during hemorrhage with control values, the method of intra¬ 
venous injection of tritiated PGE^ and collection of arterial blood was used, 
similar to that used by Hammond et al. (106). Data from control animals 
indicate that rats were able to metabolize 79% of circulating PGE2 in a sin¬ 
gle pass through the lung. This value is in agreement with values obtained 
in humans (106), demonstrating the reliability of this technique in the rat 
model. 
The results presented here indicate that hemorrhagic hypotension for 
75 minutes in the rat caused a marked decrease in in vivo single pass meta¬ 
bolism of PGE2 from 79.3% to 42.6%. There was also significant decrease in 
»*> 
the formation of the major metabolic product, 15-keto-PGE2 (38.9% to 17.3% 
of recovered radioactivity), and a smaller decrease in the formation of the 
metabolite 13,14-dihydro,15-keto-PGE2 during hemorrhage, and particularly 
implies a diminution in the activity of 15-hydroxy-PG dehydrogenase, the 
intracellular enzyme responsible for oxidation of the 15-hydroxyl moiety 
(226). 
The substantial reduction in single pass metabolism of PGE2 during 
hemorrhage is in agreement with studies of several previous investigators in 
dogs (30, 86, 128) and in baboons (74). These four studies have determined 
relative arterial and venous PG concentrations and found that the ratio of 
arterial to venous PG concentrations increased during hemorrhage. This find¬ 
ing, as Frolich pointed out (86), does not exclude the possibility of pul¬ 
monary production of PGs. Indeed, Frolich's findings suggest that pulmonary 
production of PGs is increased markedly during hemorrhage. There has been 
only one report which suggests that venous PGE reaches the arterial circula¬ 
tion in greater amounts during hemorrhage (117). These investigators found 
that hemorrhage led to an increase in arterial PGE^ levels following intra¬ 
venous injection of the PG, as measured by the crude bioassay of increased 
platelet anti-aggregatory activity. 
Flynn and Lefer (81) reported that hemorrhage does not alter the capa¬ 
city of rabbit lung homogenates to metabolize PGE. It is conceivable, how¬ 
ever, that the metabolic activity was altered during the process of isola¬ 
tion and homogenization, thus reconciling their in vitro observations with 
the in vivo studies noted above (30, 74, 86, 117, 128). A1ternatively, this 
apparent difference might represent a species difference. 
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The more likely explanation of the seeming contradiction in in vivo 
and in vitro results is that the reportedly intact intracellular metabolic 
system may not come into contact with the circulating PGs. There are two 
possible mechanisms which could account for this: a right-to-left vascular 
shunt which would bypass the lung; and vascular endothelial cell membrane 
dysfunction. 
The alterations in blood flow in the lung during hemorrhage may include 
the development of venous admixture, i.e., right-to-left shunting (249). 
Such shunts would bypass the pulmonary vascular bed, or at least the small 
vessels, thereby allowing circulating PGE to pass into the arterial circula¬ 
tion without having traversed the pulmonary bed. Thus, the PGs would not 
come into contact with the endothelial cells and could not be metabolized. 
Against this possibility is the data from blood gas studies which demonstrated 
the absense of hypoxemia after 75 minutes of hemorrhagic hypotension. This 
observation, however, does not refute the hypothesis of vascular shunting, 
but suggests rather that such shunting is not occurring to a major degree at 
that point in hemorrhage. Nonetheless, it would be instructive to determine 
the precise amount of shunting after 75 minutes of hemorrhage, since this would 
help establish the contribution of such shunting to the observed decrease in 
metabolism of circulating PGs during hemorrhage. This implies, then, that 
other possibilities must be considered as well. 
The alternative explanation is that the pulmonary vascular endothelium 
is less capable of transporting the PG into the cell where normal amounts 
of PGDH are thought to be present (81). Since membrane transport is an 
energy requiring process (26), one might speculate that ischemic cell injury 




for this process. This is consistent with the alterations in other membrane 
mediated effects seen during hemorrhage (40). On the other hand, previous 
studies have indicated that lung cellular energy levels and active trans¬ 
port are not altered during hemorrhage (232). The precise mechanism of di¬ 
minished PGE^ metabolism by the lung remains, therefore, unclear. 
In comparison with the marked decrease in metabolism of PGE£ and in ar¬ 
terial blood samples following 75 minutes of hemorrhage, analysis of lung tis¬ 
sue samples showed no difference in relative amounts of PGE£ and metabolites 
between control and hemorrhaged animals (see Table 6). The possible explan¬ 
ations for the differences between lung tissue and arterial blood metabolism 
include: 1.) that the numbers of counts recovered from lung tissue unhemor¬ 
rhaged animals were very small, so that ratios of metabolites in these sam¬ 
ples are subject to large error; 2.) the increased radioactivity which was 
associated with the M, fraction could have been due to a different PGE0 
metabolite altogether; and 3.) the delay of approximately 25 seconds be¬ 
tween arterial blood withdrawal and removal of lung tissue makes comparison 
of relative metabolite concentrations between blood and tissue questionable. 
The total number of counts per milligram of tissue was, however, increased 
during hemorrhage. This increased radioactivity could have been present 
either intracellularly or extracel1ularly, although the data reported here 
does not allow such a distinction. Nonetheless, explanations for increased 
radioactivity in hemorrhaged animals can be introduced for both locations. 
If the counts were extracellular, this would be consistent with diminished 
cardiac output during hemorrhage so that clearance of PGs would be prolonged 
and the labelled PGs could not be entirely washed out into the systemic 
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circulation. If, on the other hand, the counts were retained intracel1ularly, 
this would imply that transport of metabolites out of the cell might be the 
rate limiting step. Which of these factors predominates during hemorrhage 
is not known. 
From the data reported here it is clear that the rat is normally able 
to metabolize approximately 80% of circulating PGE^ in a single passage 
through the pulmonary vascular bed. Single pass PGE2 metabolism decreases 
to approximately 43% during hemorrhage, thereby doubling the arterial level 
of PGE^ of venous origin. The precise cause of the decreased metabolism 
during hemorrhage may encompass several factors, such as: a decrease in the 
amount of PGDH, although in vitro data does not support this hypothesis (81); 
right-to-left vascular shunting which bypasses the pulmonary circulation; 
and a diminished ability of pulmonary endothelial cells to transport PGs 
into the intracellular site of PGDH. At present, it is not possibile to 
distinguish the contributions of these hypothetical factors to the decrease 
in in vivo single pass PGE2 metabolism. 
C. Survival Studies following Hemorrhage 
The results presented in this study indicate that pretreatment with and 
infusion of indomethacin during hemorrhage caused a significant decrease in 
survival following 75 minutes of hemorrhage in rats. The survival rate de¬ 
creased from 68.8% to 29.4% (p < 0.05) in animals which were treated with 
indomethacin in doses which would give virtually complete inhibition of 
endogenous PG synthesis (77, 221). Hence, these results suggest that PG 
synthesis plays a protective role during hemorrhage in the rat. 
' 
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The mechanism of this protection is unclear. Canine studies previously 
reported, such as that of Jakschik e^ al_. (29), have demonstrated that indo- 
methacin administration causes an increase in systemic blood pressure and 
in blood loss in animals. In the present study, however, no alterations in 
blood pressure, blood loss, or reuptake were noted in indomethacin treated 
animals. This suggests that the effects of indomethacin were on organ 
perfusion or were due to local effects rather than systemic effects. 
The effects of PG synthesis blockade on organ perfusion and function 
has been studied by a number of groups of investigators. Among these effects 
is the finding that indomethacin causes decreased flow to vital organs (heart, 
brain, gut and liver, kidney) during hemorrhage by increasing vascular re¬ 
sistance (150). Since indomethacin is an effective blocker of PG synthesis, 
this study (150) implies that PGs contribute to perfusion of vital organs du¬ 
ring hemorrhage. Several studies on canine hemorrhagic hypotension have in 
fact demonstrated that indomethacin blocks the vasodilation of the renal and 
hepatic arteries which is induced by hemorrhage (23, 47, 87, 110, 111, 258). 
That PGs are the responsible agents is suggested by the finding of increased 
resistance in the renal vascular bed during hemorrhage when PGs were blocked 
with other antagonists with inhibitory mechanisms different from indomethacin. 
Thus, a number of organ function studies suggest that the protective effect 
of PGs may be on organ perfusion. 
The hypothesis that the protective effects of PGs relates to vaso- 
dilatory protection of perfusion of critical organs is attractive. In the 
rat, however, the renal vascular effects of some of the PGs are unlike those 
in other species. In particular, PGE2 is a renal vasoconstrictor and en¬ 
hances the effects of the renal sympathetics (57, 109). In most other 
< 
66. 
species the PG which opposses sympathetic activity has been identified as 
PGE2 (the effects of PG^ have not been described). Thus, unless rat renal 
sympathetic output leads to release of a different vasodilating PG, one 
might expect that PG synthesis blockade would protect renal blood flow during 
hemorrhage in the rat, precisely the opposite of the finding in dogs, as de¬ 
scribed above. Given the deleterious effect of indomethacin on overall sur¬ 
vival in rats, the notion that the mechanism of this diminution in survival 
relates to organ blood flow is more difficult to accept. It is possible, 
on the other hand, that the other vital organ beds in the rat behave in a 
manner similar to the canine renal bed and that the balance of effects, i.e., 
improvement following indomethacin in the rat kidney but worsening elsewhere, 
leads to decreased survival. Clearly this matter requires further investi¬ 
gation . 
In light of the hypothesized maintenance of vital organ perfusion as a 
mechanism of protection afforded by PGs during hemorrhage, one might consi¬ 
der the cause of death in the eight indomethacin treated rats which died sud¬ 
denly during the 75-minute hemorrhage interval. Their deaths were clearly 
associated with indomethacin treatment. It is possible, for example, that 
these eight died because of acute failure induced by impairment of flow to a 
vital organ, secondary to PG synthesis inhibition by indomethacin. This is, 
however, purely speculative. 
As a final consideration in the studies of indomethacin effect on sur¬ 
vival following hemorrhage, it ought to be pointed out that indomethacin has 
other effects besides inhibition of PG synthesis (77). Although doses used 
would have inhibited PG synthesis completely (221), they would also have 
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produced drug concentrations equivalent to those which inhibit PGDH and 
phosphodiesterase in vitro. Thus, before it is possible to conclude that the 
deleterious effects of indomethacin treatment during hemorrhage are due to 
PG synthesis inhibition, other PG inhibitors ought to be used (191). 
Given that PG blockade is detrimental, the next logical question is 
which of the PGs are the responsible protectors. Indomethacin inhibition of 
PG biosynthesis blocks production not only of primary PGs, but also of the 
endoperoxides (PGG2 and PGH^), thromboxanes, and prostacyclin, through its 
inhibitory effect on cyclooxygenase (Figure 1, step 2). In attempting to 
dissect out one part of this question, survival was assessed in animals 
treated with a combination of indomethacin (to block production of endogenous 
PG production) and PGE^ (infused at peak physiologic rates, 0.1 yg/kg/min). 
The selective replacement of PGE2 was found to be of no significant 
benefit as assessed by survival following hemorrhage. Although PGE2 appears 
to provide some benefit in that the survival rate in animals given indometha¬ 
cin plus PGE2 was greater than that in animals given indomethacin alone, this 
increase was not statistically significant. One possible cause of the ab¬ 
sence of significant PGE2 effect might be pulmonary metabolism of the intra¬ 
venous PG infusate. One might expect, however, that a significant amount of 
the infused PGE2 would have reached the arterial bed, on the basis of the 
pulmonary metabolism studies described above. In addition, indomethacin pre¬ 
treatment might have limited PGDH activity, as has been reported in vitro 
(77). Thus, a significant amount of infused PGE2 should have been able to 
reach the arterial circulation to be distributed to tissues. Since infused 
PGE2 did not improve the survival rate, circulating PGE2 does not appear 
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to be the sole responsible protective factor during hemorrhage. Other hy¬ 
potheses must, therefore, be considered. Prominent among these are: 1.) 
that locally synthesized PGE£ is the responsible factor; 2.) that a dif¬ 
ferent PG (i.e., PGI^) is the responsible factor; and 3.) that the combined 
effects of several different PGs are required for protection during hemor¬ 
rhage. 
In summary, indomethacin treatment during hemorrhage led to increased 
mortality, implying that PGs play a protective role during hemorrhagic hypo¬ 
tension. Circulating PGE2 alone was not, however, the responsible factor. 
D. Summary and Conclusions concerning Prostaglandins in Hemorrhage 
The results and discussion above point out the fact that the studies 
conducted to explore possible roles of PGs in hemorrhage have answered only 
some questions and raised many more. The evidence that PG synthesis blockade 
was detrimental to survival following 75 minutes of hemorrhagic hypotension 
in the rat suggests that PGs do, in fact, play a significant role in hemor¬ 
rhage. Where, how, and when they do is unclear. 
The use of the rat model has shown some distinct advantages, notably 
ease of carrying out experimental protocols on large numbers of animals. 
The opportunity of using large numbers of animals for further survival studies 
suggests the possibility of dissecting the complex scheme of PGs and assessing 
the role of each of several factors. Thus, use of selective blockers or of 
infusions of PGI^ and JXI\^ during hemorrhage might prove worthwhile. 
A disadvantage of the rat model lies in the small plasma volume, limit¬ 
ing the accuracy of measurement of various humoral and local vasoactive sub¬ 
stances. This is particularly true during hemorrhage. The studies reported 
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here have pointed out the pitfalls in measuring rat plasma PG levels by RIA 
during hemorrhage. 
Despite the lack of success in demonstrating alterations in plasma PG 
levels during hemorrhage, the diminution of PG metabolism in vivo has been 
established. This finding is consistent both with pulmonary shunting and 
with the alterations in other cellular and organelle functions during hemor¬ 
rhage. 
Finally, the effect of indomethacin on survival suggests that PGs play 
a protective role during hemorrhage. The inability to reverse this detri¬ 
mental effect with PGE^ alone suggests several hypotheses, as discussed 
above, which will require further investigations. In particular, studies 
directed toward understanding the role various PGs play in organ perfusion 
during hemorrhage would appear to be essential. 
2. Sepsis and Prostaglandins 
The results described above indicate that indomethacin treatment caused 
a substantial decrease in the survival of animals following early sepsis, 
but not following late sepsis. The survival rate following early sepsis in 
the indomethacin group was 25% as opposed to 83% in animals which received 
vehicle alone (controls). In contrast survival following late sepsis was 
not significantly altered by indomethacin treatment (23% vs. 30% control). 
This is the first demonstration that indomethacin treatment is deleterious 
following experimental sepsis. These results, thus, suggest: 1.) that sep¬ 
sis is a complex and evolving process; and 2.) that PGs probably play a 
role in this pricess, but whether this role is primarily vascular or inflam¬ 
matory is not known. 
• l ■>. 
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The observation that sepsis is an evolving process is evidenced by the in¬ 
creased mortality of control animals in late sepsis as opposed to early sep¬ 
sis. This data corresponds wi th earlier data from this laboratory which in¬ 
dicated that rats in the early septic phase have a hyperdynamic circulation 
and are hyperglycemic. In contrast, late septic animals show cardiovascu¬ 
lar depression and hypoglycemia (41). Since the mortality rate of animals 
following late sepsis was significantly more than following early sepsis, 
this suggests that mortality varies inversely with cardiovascular status of 
the animal. This is precisely what has been observed in clinical settings 
(189). 
Related to this observation is the finding that indomethacin alters sur¬ 
vival following early sepsis but not late sepsis. These results suggest that 
PGs play a vital role in homeostasis during early sepsis and that factors 
other than PG may play a more important role during late sepsis. Certainly 
the profound hypoglycemia and circulatory changes seen in late sepsis would 
be expected to overshadow any more subtle hemodynamic alterations attributa¬ 
ble to the PGs. Thus, PG synthesis blockade would not be expected to alter 
survival following late sepsis and the results presented above support this 
notion. 
Since indomethacin, which blocks PG synthesis, affected the survival of 
animals following early sepsis, it is essential to ascertain the precise role 
PGs play during sepsis. One possible role of PGs is that they may regulate 
organ and local tissue perfusion analagous to their postulated role in hemor¬ 
rhage. It is conceivable that indomethacin alters the hyperdynamic circula¬ 
tion of early sepsis and that this is detrimental. As discussed above, how¬ 
ever, indomethacin may inhibit other enzymes (PGDH, phosphodiesterase) and 
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neutrophil function (77). Thus, the use of indomethacin alone does not 
necessarily prove that PG synthesis inhibition is the only responsible fac¬ 
tor for increased mortality following indomethacin treatment. In addition, 
the PGs are believed to contribute actively to the inflammatory response 
(119). Thus, it is conceivable that the deleterious effects of indometha¬ 
cin following early sepsis could relate more to the modification or inhibi¬ 
tion of normal host defenses than to circulatory alterations. The mechanism 
of action of indomethacin could, therefore, be due to inhibition of PG re¬ 
lated changes in host defenses (119), to prevention of the capability of 
bactericidal leukocytes to reach the site of infection (77), or to deleterious 
circulatory alteration. Clearly, this area requires further investigation. 
To summarize, using a reliable model of sepsis in rats, the effects 
of indomethacin treatment in both early and late sepsis have been studied. 
The results presented indicate that indomethacin treatment following early 
sepsis was deleterious, but did not alter the already high mortality of late 
sepsis. This implies that PGs play a significant role in sepsis, but that 
their significance may be eclipsed by other factors as sepsis evolves. It 
is not clear whether the effects of PGs in early sepsis relate primarily to 
vascular function or to the inflammatory reaction; this requires further 
investigation. 
Finally, the differences between sepsis and endotoxin shock are made 
apparent from this study. The clear demonstration of a deleterious effect 
of indomethacin in early sepsis is in striking contrast to observations 
during endotoxemia (63, 66, 72, 73, 75, 76, 104, 113, 115, 203-206, 214). 
Indeed, most studies using endotoxin have found benefits of PG synthesis 
inhibition, particularly related to the acute changes of systemic 
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hypotension and pulmonary hypertension (63, 66, 72, 73, 76, 104, 113, 115, 
116, 203-206). Such changes are not, however, observed in sepsis. The 
altered state observed in late endotoxin shock appears, however, to paral¬ 
lel that late sepsis, at least in some respects. The circulation is depres¬ 
sed in both conditions, and mortality is high. Consistent with these ob¬ 
servations is the finding that indomethacin does not produce dramatic ef¬ 
fects on survival following either late sepsis or endotoxin shock. On ac¬ 
count of the hemodynamic similarities between endotoxin shock and late sep¬ 
sis, it is conceivable that endotoxin contributes to the conditions found 
in sepsis. To conclude, however, that the pathophysiology of late sepsis 
is identical to that of early sepsis would not appear to be justified, on 
the basis of the different hemodynamic patterns (45) and response to indo¬ 
methacin. Sepsis seems to be a pathophysiologic process involving a num¬ 
ber of factors. These include the host defense, circulatory, and endocrine- 
metabolic systems, as well as a number of hormones related to these sys¬ 
tems, including PGs. Further studies using a sepsis model, such as has 
been described here, will contribute to the understanding of the complex 





The following pages comprise a brief compendium of the salient aspects 
of PG physiology as gleaned from a number of review articles which are cited 
and to which the reader is directed for further and fuller description. In 
addition there is a recent monograph (119) and three reviews of the clinical 
aspects of PGs (135, 183, 184). 
A. Biochemistry (see ref. 11, 120, 156, 229-231, 264). The PGs are a set 
of 20 carbon chain fatty acids containing one to three double bonds and a 
five carbon ring (Cg-C^)- They are subdivided into three series, corres¬ 
ponding to the number of double bonds, and into several classes, according 
to the structure and substitution on the ring. Figure 1 shows the structures 
and synthetic pathways of the most common series, the 2 series, as well as 
the related thromboxanes, and the metabolic degradation products. The pre¬ 
cursors for PG synthesis are essential unsaturated fatty acids, such as aracha- 
donic acid (AA), which form part of the cell membrane phospholipids, from 
which they are released by the action of phospholipase A^. This enzyme is 
2+ 
affected by many factors, among which Ca and cAMP have been implicated. 
The conditions which lead to release of AA and subsequent PG synthesis in¬ 
clude mechanical stimulation, anoxia, ischemia, anaphylaxis, embolization, 
and probably several others (262). Free AA is then transformed to the short¬ 
lived endoperoxide PGG^ by the enzyme cyclooxgenase (also called PG synthe¬ 
tase, EC 1.14.99.1), which is localized on the inner leaflet of cell mem¬ 
brane bilayers. . PGG^ then undergoes further transformation to a thromboxane 
(TXA^), prostacyclin (PGI^), or a primary prostaglandin (PGEg or PG F^^) - The 
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enzymes responsible for these reactions are tissue-specific (e.g., platelets 
make thromboxanes almost exclusively, whereas vascular endothelium makes none 
under normal circumstances). 
The PGs, however, have short half-lives in plasma, ranging from 30 
seconds for TXA^ to several minutes for PGs E2, F^, and I^. Furthermore, 
the primary PGs (E and F) disappear rapidly from the circulation (67); in 
particular, they disappear during passage through the pulmonary circulation. 
This has been documented in cats (48), dogs (217), guinea pigs (4), rabbits 
(117), rats (202), and humans during cardiac catheterization (95) and open 
heart surgery (106). That lungs metabolize the PGs is consistent with the 
observation that the pulmonary vasculature metabolizes many other vasoactive 
compounds (19, 89, 227, 270). Specifically, metabolism by the vascular endo¬ 
thelium is seen to be energy dependent (26), carrier mediated (27), and anionic 
(28), implying intracel1ular metabolism of PGs. The responsible enzymes have 
been identified and purified (226). The most important of these for the pri¬ 
mary PGs is 15-hydroxy PG dehydrogenase (PGDH, EC 1.1.1.141), which reduces 
the 15-hydroxyl moiety to a keto group, thereby diminishing substantially the 
activity of the PG. Less important is PG A13 reductase which reduces the 13,14 
double bond, rendering the PG inactive. The presence of these enzymes has 
been demonstrated in a number of tissues (2) and in vivo studies have been 
conducted to substantiate in vitro results (180, 181, 186, 187). More recent 
studies on PG metabolism have established that the turnover of PGDH is very 
rapid (29). PGDH can be decreased by such factors as oxygen toxicity (61) 
and increased by others such as pregnancy and progesterone (59). 
To summarize, the PGs are synthesized intracellularly in response to a 
number of stimuli by well established pathways. They are inactivated rapidly 
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in plasma and by the pulmonary vasculature. 
B. Cardiovascular Effects (see ref. 114, 148, 182, 185, 222, 265). The ef¬ 
fects of PGs on the cardiovascular system are manifold. In general, PGE2 
and PGI^ are vasodilators and PGF2 and TXA£ are vasoconstrictors. In both 
pairs, the latter is more effective. 
The cardiac effects (190, 242, 261) include: vasodilation of the coro¬ 
nary bed by PGE^ and PGI^ (195) and constriction by PGF2a and TXA2 (251); 
negative inotropic effects by PGE-j and E^ (142, 199, but also see 247); ar- 
rhythmogenic potential of PGF^^ (130, 141); and opposing anti-arrhythmic ac¬ 
tivity of the PGEs (133, 135, 157, 279). The identity of the PGs primarily 
responsible for control of the coronary bed is still being debated, through 
current evidence favors PGI^ with a minor role ascribed to PGE2. 
The pulmonary vascular bed is not only responsible for metabolism of 
circulating primary PGs but is also controlled by the PGs (269). PGE-j dimin¬ 
ishes vascular tone by relaxation of smooth muscle (134), whereas PGF2a causes 
increased pulmonary artery pressure. Infusion of arachadonic acid also pro¬ 
duces pulmonary hypertension (273), as does hypoxia and anaphylaxis; all of 
these may be inhibited by PG synthesis blockade. Patency of the neonatal 
ductus arteriosus appears to be dependent on vasodilatory PGs (245). 
Similar effects of PGs E0 and F0 have been observed in the mesenteric 
c. la 
(171, 238), hepatic (215), skeletal muscular (171), and cutaneous vessels 
(219). Thromboxane ^ has been demonstrated to be a potent cerebral vaso¬ 
constrictor (62) and constricts peripheral vessels as well (68). These ef¬ 
fects are not surprising in view of the demonstration that vascular smooth 
muscle is nearly universally relaxes by PGE2 and contracted by PGF^^ (9). 
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C. Renal Effects (16, 57, 70, 147, 168, 280). PGs have been implicated in 
five aspects of renal function: distribution of intrarenal blood flow, regu¬ 
lation of systemic blood pressure, control of renin release, effects on tubu¬ 
lar function, and mediation of erythropoietin stimulation. 
Flow in intrarenal vessels, as in most of the microvasculature, is af¬ 
fected by PGs. PGs are synthetized in the medulla (112), but exhibit their 
major distributional effect in promotion of flow to the cortex (22) by vaso¬ 
dilation. This effect appears to be primarily reactive; i.e., they probably 
do not control basal resistance, but are synthesized in conditions of altered 
flow (200). It should be noted that PGE^ has been found to be a vasoconstric¬ 
tor in the rat kidney. However, whether PGI^ or PGE2 is the major dilator is 
not known (nor are the effects of PGin the rat renal bed). 
The initial description of "medullin," a renal hypotensive lipid, promo¬ 
ted investigation into possible roles for PGs in opposing systemic hyper¬ 
tension (263). Subsequent work indicates that the PGs may participate as 
intermediates for other humoral substances and as intrinsic renal vasodilators 
rather than as circulating hormones. PGE2 (or PG^) may exhibit effects 
through diuresis accountable to renal vasodilation (18), as well as through 
control of renin. 
The mechanism of renin release is still unclear. As demonstrated by 
indomethacin blockade of PG synthesis, renin release is dependent on PGs (277), 
a finding supported by the demonstration that indomethacin inhibition of renin 
release be overcome by infusion of PGE2- The most recent suggestion (196) is 




The effects of renal PGs on fluid and electrolyte balance is also the 
subject of continuing debate (16, 57, 166, 168, 256). PGE2 appears to func¬ 
tion as a natriuretic, perhaps on the basis of its vasodilatory capacity. 
PGF2a has been reported to conserve sodium. One current theory (168) postu¬ 
lates that PGs E2 and F2a control sodium excretion, and they in turn are con¬ 
trolled through kinin effects on 9-ketoreductase (the enzyme which converts 
PGE2 to PGF2a). In addition, PGE2 is reported to be an antagonist of anti¬ 
diuretic hormone (ADH), through actions on cAMP (57, 201). Thus, many theor 
ies of PG action in the kidney have been proposed, but no unifying hypothe¬ 
sis has been postulated as yet. 
Evidence for a role of PGs in erythropoietin stimulation has been pre¬ 
sented (101). Further substantiation, however, is required. 
In summary, the most important functions of PGs in the kidney are re¬ 
active. They are synthesized in response to hemodynamic and hypoxic insults 
In addition, they appear to mediate effects of some hormones (ADH, kinins). 
D. Pulmonary Effects (see ref. 65, 121, 163, 164, 228, 237). As described 
previously, the pulmonary vascular bed both plays an important role in PG 
metabolism and is controlled by PGs. PGs are also capable of producing ef¬ 
fects on airway smooth muscle analogous to effects observed on vascular 
smooth muscle; viz., PGE2 is a potent bronchodilator and PGF2ais the most 
potent bronchoconstrictor yet found. The lung additionally functions as an 
active secretor of PGs, particularly during hypoxia and anaphylaxis, suggest 
ing that PGs may play a role in control of ventilation-perfusion matching. 
E. Gastrointestinal Effects (see ref. 52, 216). The PGs are known to have 
striking effects on gastrointestinal smooth muscle, PGE2 being a prominent 
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and potent stimulus to contraction of longitudinal smooth muscle and relaxer 
of circular smooth muscle. Cholera toxin diarrhea has been linked to pro¬ 
duction of PGs. PGE2 has also been found to possess the capacity to protect 
against ulcer formation. Correspondingly, PG inhibitors have long been asso¬ 
ciated with ulcer production. Current theory holds that PGE£, through cAMP, 
both inhibits histamine stimulated H+ release and itself leads to secretion 
of the gastrointestinal polysaccharides, glycosaminoglycans. 
F. Endocrine Effects. Most of the work on the endocrine effects of PGs have 
centered around either reproductive roles of PGs or the interactions of PGs 
with cAMP. Infusion of PGE-j and PGE^ have, in addition, been reported to 
cause increased plasma glucose by means of glucagon stimulation and inhibition 
of glucose related insulin secretion (207, 218, 225). Conversely, aspirin 
blockade of PG synthesis is related to diminished glucose levels, especially 
in diabetics, although the mechanism is unclear (173). 
G. Nervous System Effects (see ref. 32, 85, 109, 159). The effects of PGs 
on the nervous system fall into two classes, central and autonomic. The cen¬ 
tral effects include a putative role in fever (66) and effects on neurotrans¬ 
mission (86). More important are the peripheral autonomic effects. PGE en¬ 
hances cholinergic transmission (105). Adrenergic transmission, however, is 
inhibited prejunctionally by PGs, presumably by PGE£. The postulated mecha- 
2+ 
nism is interference with the movement of Ca in stimulation-contraction 
coupling,but this is speculative. Rat renal sympathetic nerves differ from 
other species in that PGE^ enhances sympathetic effects. In all other cir¬ 
cumstances, however, PGs again appear to subserve the function of maintenance 
of local homeostasis in the face of systemic alterations. 
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H. Control of Local Circulation (see ref. 31, 125, 167, 172, 246, 268). In 
addition to negative feedback exerted on adrenergic nerve terminals and con¬ 
sequent modulation of adrenergic stimuli, the PGs have been found to modu¬ 
late or mediate the effects of the rnicrovasculature to a number of other 
vasoactive substances including antagonism of angiotensin II induced vaso¬ 
constriction (90, 192)and mediation of bradykinin induced vasodilation (1, 
94, 252). They do not appear to be involved in the effects of exogenous dopa¬ 
mine (54). Possible roles in relation to serotonin are undetermined. PGs 
are believed to be responsible for human reactive and functional hyperemia 
(139). Thus, the PGs, in addition to a direct vasodilatory function, also ap¬ 
pear to modulate control of the terminal bed by their interactions with other 
vasoactive stimuli. The general principle of PG synthesis in response to al¬ 
terations in local circulatory status is thus seen to hold at all levels of 
the mammalian cardiovascular system. 
I. Hematologic Effects (see ref. 88, 96, 162, 174). PGE-| and, more recently, 
PGI^ have been recognized as potent agents in inhibiting platelet aggregation. 
The mechanism is believed to be modulation of platelet cAMP (97, 251). In 
addition, TXA^ is known to be a substance formed by platelets capable of stimu¬ 
lation of platelet aggregation. These findings have been documented in clini¬ 
cal settings (51, 102, 160, 248). At present, it is believed that the balance 
of platelet TXA2 and endothelial PG^ controls in vivo platelet activity. 
J. Cyclic Nucleotides and Prostaglandins (see ref. 88, 136, 144, 231, 236, 
257). Elevation of intracellular cAMP following PGE2, PGE-j , and PG^ has 
been noted in many other tissues besides platelets. This has been invoked 
as a unifying hypothesis to explain PG effects. This "middleman hypothesis" 
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(88), which postulates PGs as intermediates for cAMP production is support¬ 
ed by the observed prolongatin of PGE vascular effects by phophodiesterase 
inhibition (56). 
It, therefore, seems unquestionable that PGs interact with cyclic nu- 
clotides. Yet many related questions remain unanswered: 1.) it is unclear 
how PG synthesis is initiated; 2.) the role of Ca in relation to PGs re¬ 
mains a mystery; 3.) whether PGs subserve a circulatory role is also there¬ 
by brought into controversy. As to the question of stimulus for PG synthesis, 
it is clear that virtually all noxious stimuli evoke PG biosynthesis. Some 
of these stimuli such as mechanical injury (161) might involve direct physi¬ 
cal destruction of membranes, thereby freeing arachadonic acid for PG bio¬ 
synthesis. Other stimuli, such as hypoxia, compromised perfusion, nucleo- 
2+ 
tides (194), adenosine (7), Ca (278), or other electrolyte alterations may 
activate phospholipase and PG synthetase as their mechanism of actions. These 
three stimuli of PG synthesis have in common the function of PGs as messengers 
from cell membrane to cytoplasm. 
The interaction of PGs and cyclic nucleotides is complicated by the 
2+ 
unclear role of cytoplasmic calcium. Indeed, PGs, cAMP, and Ca seem to 
be involved in an intracellular mdnage h trois. PG synthesis is increased 
2+ 
by Ca stimulation of phospholipase but PGs are capable of inducing calcium 
release from intracellular mitochondria (36). PG synthesis appears to be 
dependent on the oxidation-reduction capability of the cell (193), and, 
therefore, indirectly on nucleotides and cyclic nucleotides. At present, 
.. 
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it is possible only to state that PGs may serve as intracellular hormones, 
(291), without certain understanding of their roles and mechanisms. 
The acceptance of PGs as intracellular hormones leads to the question 
of their circulatory role. Yet their measurable release in response to 
extracellular insults and the extensive capacity of vascular endothelium to 
metabolize PGs argues for a circulatory role. Furthermore, PG receptors 
have been demonstrated (143). It seems likely, therefore, that PGs serve as 
the messenger of the cell membrane both to the cytoplasm and to other local 
cell populations. The pulmonary bed serves to assure this localization, at 
least of the primary PGs. 
K. Measurement of Prostaglandins. One of the major problems in PG research 
has been measurement of PGs (191). Initially, investigators used a super¬ 
fusion bioassay to measure PGs, usually combined with chromatography. This 
method, however, presents significant problems in specificity (34, 44). 
Other methods involving enzymatic and receptor assays have been abandoned 
for lack of both sensitivity and specificity (3, 143). 
Radioimmunoassay (RIA) has also been used (125) since the development 
of specific antisera, although problems with this technique have been per¬ 
sistent (98, 208). Specifically, measurements of PGs have generally result¬ 
ed in plasma levels in the nanomolar range, which differs by two to three or¬ 
ders of magnitude from other more recent and reliable measurements (84). The 
cause of erroneous plasma PG measurement is not clear. The possibility of 
lack of antiserum specificity and of non-specific binding of antibodies by 
non-PG plasma elements have been proposed (98). Moreover, the plasma half- 
life of these compounds is very short. This observation in conjunction with 
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the realization that PGs are primarily local hormones, implies that measure¬ 
ment of levels of circulating PGs might not indicate either the rate of local 
synthesis of PGs or the physiologic effects due to PGs. Thus, the determina¬ 
tion of circulatory PG levels may be meaningless. RIA does, nonetheless, hold 
promise for future use. 
The current gold standard for measurement of PGs is the combined use of 
gas chromatography-mass spectrometry (84). The major drawbacks of this method 
are cost and time required. 
The several techniques used require caution in acceptance of results of 
PG measurement in plasma. At present, the combination of PG synthesis block¬ 
ade is generally required in conduction with plasma measurement. 
L. Pharmacologic Manipulations of the Prostaglandins (see ref. 74). Research 
on PGs received a great boost with the demonstration in 1971 that aspirin and 
several other non-steroidal anti-inflammatory drugs inhibit PG synthesis (78). 
Subsequently, these compounds have been of great value in delineating PG ef¬ 
fects. The drug concentrations required for inhibition have been more dif¬ 
ficult to establish,however. The IC^q of indomethacin, the most commonly used 
and most potent agent, has been assessed in vitro in guinea pig lungs to be 
12 - 34 ng/ml (69). A recent in vivo study in rat kidneys showed a 69% re¬ 
duction in PGs as assessed by bioassay and an in vitro inhibition of 97%.(221). 
Membrane stabilization and corollary inhibition of arachadonic acid re¬ 
lease has been reported to be the mechanism of action of corticosteroid in¬ 
hibition of PG synthesis (157). Other membrane active agents, particularly 
local anesthetics, can also inhibit in vitro PG synthesis (145), perhaps be- 
2+ 
cause of Ca effects. 
' 
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The existence of compounds which inhibit the action of PGs peripherally 
has also been described (24). These agents, because of competition for bind¬ 
ing sites, may also inhibit PG degradation enzymes, such as PGDH (44). 
To date, however, few inhibitors of PG metabolism have come into wide 
use, although diuretics have been reported to do so (250). The rapid turn¬ 
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